[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 108
1. Walts AE, Lechago J, Hu B, Shwayder M, Sandweiss L, Bose S: P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN). Clin Med Pathol; 2008;1:7-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN).
  • BACKGROUND: Significant variation is reported in the diagnosis of HPV-associated AIN.
  • We previously observed that band-like positivity for p16 in >90% of contiguous cells coupled with Ki67 positivity in >50% of lesional cells is strongly associated with high grade AIN.
  • This study was undertaken to determine if addition of p16 and Ki67 immunostaining would reduce inter- and intraobserver variability in diagnosis and grading of AIN.
  • DESIGN: H&E stained slides of 60 anal biopsies were reviewed by three pathologists and consensus diagnoses were achieved: 25 negative, 12 low (condyloma and/or AIN I) and 23 high (9 AIN II and 14 AIN III) grade lesions.
  • RESULTS: Addition of p16 and Ki67 immunostains reduced intra- and interobserver variability, improved concurrence with consensus diagnoses and reduced two-step differences in diagnosis.
  • Negative and high grade AIN diagnoses showed the most improvement in concurrence levels.
  • CONCLUSION: Addition of p16 and Ki67 immunostains is helpful in the diagnosis and grading of AIN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):471-9 [10950374.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Bull Cancer. 2003 May;90(5):405-11 [12850763.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]
  • [Cites] Obstet Gynecol. 1990 Jan;75(1):131-3 [2296409.001]
  • [Cites] J Clin Pathol. 1994 Nov;47(11):1032-4 [7829679.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8 [14530670.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):969-87, ix [17996800.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1986 Sep;94(5):343-9 [3766143.001]
  • [Cites] Clin Obstet Gynecol. 1967 Dec;10(4):748-84 [4172733.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • (PMID = 21876646.001).
  • [ISSN] 1178-1181
  • [Journal-full-title] Clinical medicine. Pathology
  • [ISO-abbreviation] Clin Med Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3159996
  • [Keywords] NOTNLM ; Ki67 / P16 / anal intraepithelial neoplasia (AIN) / condyloma / human papilloma virus (HPV) / interobserver variability / intraobserver variability
  •  go-up   go-down


2. Baynouna LM, Revel AD, Nagelkerke NJ, Jaber TM, Omar AO, Ahmed NM, Nazirudeen MK, Al Sayed MF, Nour FA, Abdouni S: Associations of cardiovascular risk factors in Al Ain, United Arab Emirates. Cardiovasc Diabetol; 2009;8:21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations of cardiovascular risk factors in Al Ain, United Arab Emirates.
  • AIM: To investigate the prevalence and associations among cardiovascular risk factors in this population, and explore to what extent associations can be explained by the metabolic syndrome according to ATP-III criteria.
  • METHOD: A community based survey, of conventional risk factors for cardiovascular disease was conducted among 817 national residents of Al Ain city, UAE.
  • CONCLUSION: In this population risk-factors cluster, but associations do not appear to be explained by the presence/absence of the ATP-III metabolic syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Isr Med Assoc J. 2000 Mar;2(3):207-10 [10774268.001]
  • [Cites] Am J Prev Med. 2008 Oct;35(4):357-63 [18779029.001]
  • [Cites] J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):17-22 [11821633.001]
  • [Cites] Diabet Med. 2002 Nov;19(11):954-7 [12421434.001]
  • [Cites] J Epidemiol Community Health. 2003 Sep;57(9):734-9 [12933782.001]
  • [Cites] East Mediterr Health J. 2002 Mar-May;8(2-3):374-85 [15339127.001]
  • [Cites] Nihon Ronen Igakkai Zasshi. 1993 Sep;30(9):778-86 [8230791.001]
  • [Cites] Heart. 1998 Mar;79(3):248-52 [9602657.001]
  • [Cites] Diabetes Care. 2005 Sep;28(9):2289-304 [16123508.001]
  • [Cites] J Hum Hypertens. 2005 Nov;19(11):861-8 [16034449.001]
  • [Cites] Hypertension. 2006 Mar;47(3):403-9 [16432042.001]
  • [Cites] Endocr Pract. 2006 Jan-Feb;12 Suppl 1:20-4 [16627375.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1237-47 [16762930.001]
  • [Cites] Medicina (Kaunas). 2006;42(7):559-65 [16861837.001]
  • [Cites] Am J Med. 2006 Oct;119(10):812-9 [17000207.001]
  • [Cites] J Am Coll Cardiol. 2007 Jan 30;49(4):403-14 [17258085.001]
  • [Cites] Diabetes Educ. 2007 Jan-Feb;33(1):69, 74-5, 77-8 [17272794.001]
  • [Cites] Epidemiol Rev. 2007;29:115-28 [17494056.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Dec;78(3):369-77 [17532085.001]
  • [Cites] J Hypertens. 2008 Feb;26(2):169-77 [18192826.001]
  • [Cites] Diabetes Care. 2008 Apr;31(4):732-4 [18235051.001]
  • [Cites] Diabetes Care. 2008 Apr;31(4):684-9 [18252904.001]
  • [Cites] Cerebrovasc Dis. 2008;25(6):539-47 [18480607.001]
  • [Cites] Obesity (Silver Spring). 2008 Jul;16(7):1622-35 [18421260.001]
  • [Cites] Am J Cardiol. 2008 Jul 15;102(2):188-91 [18602519.001]
  • [Cites] Saudi Med J. 2008 Aug;29(8):1173-8 [18690314.001]
  • [Cites] East Mediterr Health J. 2008 May-Jun;14(3):647-53 [18720629.001]
  • [Cites] Am J Med. 2000 Nov;109(7):538-42 [11063954.001]
  • (PMID = 19371412.001).
  • [ISSN] 1475-2840
  • [Journal-full-title] Cardiovascular diabetology
  • [ISO-abbreviation] Cardiovasc Diabetol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2673216
  •  go-up   go-down


3. Hamed GM, Bahgat NM, El-Agaty SM, Soliman GZ, Emara MM: Effects of a soybean protein diet on ovariectomised female albino rats subjected to myocardial infarction. Singapore Med J; 2010 Oct;51(10):781-9
MedlinePlus Health Information. consumer health - Heart Attack.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study was conducted on 30 adult female albino rats, which were divided into three groups: Group I comprised the sham-operated rats; Group II, the ovariectomised (OVX) rats fed a standard diet; and Group III, OVX rats fed a standard diet supplemented with SP (OVX plus SP).
  • RESULTS: The biochemical studies showed a significant increase in plasma CPK (Group II), MDA and triacylglycerol (Groups II and III) levels compared to Group I.
  • Significant increases in T4 and TSH were found in Group III compared to Group II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Singapore Med J. 2010 Nov;51(11):906
  • [ErratumIn] Singapore Med J. 2011 Oct;52(10):770
  • (PMID = 21103813.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Cholesterol, LDL; 0 / Cholesterol, VLDL; 0 / Lipids; 0 / Phytoestrogens; 0 / Soybean Proteins; 0 / Triglycerides
  •  go-up   go-down


Advertisement
4. Hamed E, Attia MS, Bassiouny K: Synthesis, spectroscopic and thermal characterization of copper(II) and iron(III) complexes of folic acid and their absorption efficiency in the blood. Bioinorg Chem Appl; 2009;:979680

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis, spectroscopic and thermal characterization of copper(II) and iron(III) complexes of folic acid and their absorption efficiency in the blood.
  • xH(2)O, where (M = Cu(II) or Fe(III), n = 2 or 1, FO = folate anion, x = 2 or 3 with respect), were prepared, and their absorption efficiency in rodent's blood was determined.
  • Biological application proved that Cu(II) and Fe(III) complexes were absorbed more efficiently in rodent blood than folic acid itself.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 May 1;55(9):1894-901 [7794383.001]
  • [Cites] JAMA. 1995 Dec 6;274(21):1698-702 [7474275.001]
  • [Cites] Ann Neurol. 1982 Nov;12(5):479-84 [6185039.001]
  • [Cites] Nutr Rev. 2004 Jun;62(6 Pt 2):S3-12; discussion S13 [15298442.001]
  • [Cites] J Nutr. 2003 Mar;133 Suppl 3:941S-947S [12612180.001]
  • [Cites] Trends Neurosci. 2003 Mar;26(3):137-46 [12591216.001]
  • [Cites] J Child Neurol. 2002 May;17(5):353-6 [12150582.001]
  • [Cites] Ageing Res Rev. 2002 Feb;1(1):95-111 [12039451.001]
  • [Cites] Int J Dev Neurosci. 2006 Feb;24(1):3-8 [16442260.001]
  • [Cites] Epilepsy Behav. 2005 Sep;7(2):172-81 [16054874.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):403-10 [15964170.001]
  • [Cites] J Nutr Biochem. 1999 Feb;10(2):66-88 [15539274.001]
  • [Cites] J Chromatogr A. 1999 Sep 3;855(1):237-45 [10514988.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):31-8 [9097976.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2071s-2077s [1544143.001]
  • (PMID = 19746175.001).
  • [ISSN] 1687-479X
  • [Journal-full-title] Bioinorganic chemistry and applications
  • [ISO-abbreviation] Bioinorg Chem Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2738859
  •  go-up   go-down


5. El-Meteini M, Hamza A, Abdalaal A, Fathy M, Bahaa M, Mukhtar A, Abouelfetouh F, Mostafa I, Shaker M, Abdelwahab S, El-Dorry A, El-Monayeri M, Hobballah A, Sabry H: Biliary complications including single-donor mortality: experience of 207 adult-to-adult living donor liver transplantations with right liver grafts. HPB (Oxford); 2010 Mar;12(2):109-14
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After modified Clavien classification, biliary complications were graded as grade I (n= 10), grade II (n= 2), grade III (n= 14) and grade V (n= 1).
  • Grade I and II (n= 12) biliary complications were successfully managed conservatively.
  • Grade III cases were treated using ultrasound-guided aspiration (USGA), endoscopic retrograde cholangiography (ERCP) and surgery in 10, 2 and 2 donors, respectively.
  • Single donor mortality (Grade V) (0.4%) occurred after uncontrolled biliary leakage with peritonitis that necessitated exploration followed by ERCP with stent insertion but the donor died on day 43 as a result of ongoing sepsis.

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Transplant. 2004 Jan;4(1):2-3 [14678027.001]
  • [Cites] Transplant Proc. 2003 Nov;35(7):2783-6 [14612119.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Surgery. 1992 May;111(5):518-26 [1598671.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1233-4 [7909905.001]
  • [Cites] Transplant Proc. 1996 Jun;28(3):1669-70 [8658831.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):261-9; discussion 269-70 [9339932.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):269-74 [9488526.001]
  • [Cites] Transplantation. 1999 Jan 27;67(2):321-7 [10075602.001]
  • [Cites] Am J Transplant. 2005 Jul;5(7):1694-703 [15943628.001]
  • [Cites] Am J Transplant. 2005 Nov;5(11):2764-9 [16212638.001]
  • [Cites] Transplant Proc. 2005 Sep;37(7):3141-3 [16213330.001]
  • [Cites] Br Med Bull. 2005;75-76:15-28 [16474043.001]
  • [Cites] Liver Transpl. 2006 Jan;12(1):24-30 [16498709.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):755-9 [16494593.001]
  • [Cites] Liver Transpl. 2006 Jun;12(6):920-7 [16721780.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1373-85 [16732172.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):110-7 [17197973.001]
  • [Cites] Transplantation. 2009 Feb 15;87(3):445-50 [19202452.001]
  • [Cites] Liver Transpl. 2000 Jan;6(1):3-20 [10648573.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):336-40 [10722038.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):824-31 [10816625.001]
  • [Cites] Transpl Int. 2000;13(5):333-9 [11052268.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S64-5 [11084088.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):425-33 [11296114.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1038 [11932469.001]
  • [Cites] Transplantation. 2002 Jun 27;73(12):1896-903 [12131684.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1078-88 [12190671.001]
  • [Cites] Liver Transpl. 2003 Jun;9(6):581-6 [12783399.001]
  • [Cites] Radiology. 2004 Feb;230(2):443-9 [14699180.001]
  • (PMID = 20495654.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2826668
  •  go-up   go-down


6. Chung AP, Rosenfeld DB: Intraoperative high-resolution anoscopy: a minimally invasive approach in the treatment of patients with Bowen's disease and results in a private practice setting. Am Surg; 2007 Dec;73(12):1279-83
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anal intraepithelial neoplasia III (AIN III) is a risk factor for anal cancer with poor curative results and high morbidity.
  • High-resolution anoscopy (HRA) is a minimally invasive means of identifying and treating AIN III early.
  • We retrospectively reviewed HRA in the treatment of AIN III in a community setting.
  • From January 2002 through November 2005, 76 patients with AIN III diagnosed by anal Pap smear, colposcopy, or biopsy underwent HRA for diagnosis and treatment.
  • Twenty-one patients with AIN III on initial HRA underwent follow-up HRA for reassessment and treatment at 6 months.
  • Twelve of 21 (57%) had intraanal recurrence/persistence; nine of 21 (43%) had no AIN III.
  • HRA is an alternative tool to treat AIN III and can be performed in a community setting yielding results comparable to the university setting.
  • As the prevalence of AIN III increases, it will be more important for community surgeons to treat AIN III with HRA.
  • [MeSH-major] Bowen's Disease / pathology. Bowen's Disease / surgery. Endoscopy, Gastrointestinal / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anal Canal. Community Health Services. Follow-Up Studies. Humans. Male. Middle Aged. Private Practice. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186390.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Scholefield JH, Castle MT, Watson NF: Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg; 2005 Sep;92(9):1133-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade anal intraepithelial neoplasia.
  • BACKGROUND: The natural history of anal intraepithelial neoplasia (AIN) is uncertain.
  • METHODS: All patients were diagnosed with high-grade AIN (AIN III) between 1994 and 2003.
  • Diagnosis was by full-thickness biopsy and histopathological examination.
  • Prospective data were collected regarding recurrence, postoperative complications and progression to invasive carcinoma.
  • Excision of localized high-grade AIN was carried out in 28 patients with minimal morbidity.
  • Six patients were systemically immunosuppressed at diagnosis, all of whom had multifocal perianal lesions.
  • Three immunosuppressed patients developed invasive anal squamous carcinoma during follow-up.
  • CONCLUSION: AIN III appears to have a relatively low potential for malignant transformation in the immunocompetent patient.
  • However, immunosuppressed patients are more likely to have extensive AIN III and a greater risk of malignant change.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Prospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16044425.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Parés D, Mullerat J, Pera M: [Anal intraepithelial neoplasia]. Med Clin (Barc); 2006 Nov 18;127(19):749-55
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia].
  • [Transliterated title] Neoplasia intraepitelial anal.
  • Human papillomavirus (HPV) is responsible for anal condylomata, anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma.
  • AIN is a premalignant condition that can progress to invasive carcinoma through different grades of severity of the disease called AIN I, AIN II and AIN III.
  • This paper looks at the current definition, diagnostic methods and management of AIN.
  • The incidence of AIN has increased significantly in the last decades.
  • The groups at risk are mainly patients with infection with human immunodeficiency virus, immunossuppressed patients and patients affected by HPV related diseases (e.g., cervical cancer or anal condyloma).
  • Accurate diagnosis of AIN lesions consists of accurate grading and disease extension.
  • Low grade AIN (AIN I) or in extensive lesions, follow-up is advised to determine the possible evolution to anal squamous cell carcinoma.
  • In cases of more severe and localized lesions (AIN II and AIN III), surgical resection should be considered if the predictive postoperative morbidity is low.
  • Screening programs for AIN are not currently in place and there might be much effort to study the management of HPV in these patients.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198654.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 58
  •  go-up   go-down


9. Kruijt B, van der Snoek EM, Sterenborg HJ, Amelink A, Robinson DJ: A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia. Photodiagnosis Photodyn Ther; 2010 Mar;7(1):3-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia.
  • The objective of this study was to develop an applicator for delivery of light and monitoring of photodynamic therapy (PDT) in the anal cavity for treatment of anal intraepithelial neoplasia grade III (AIN III), which can progress to invasive anal cancer.
  • For light delivery and monitoring of PDT, an applicator based on standard anoscopy equipment was developed which facilitates, in addition to a light treatment fiber, fiber optic probes to monitor blood saturation, blood volume, fluorescence and fluence (rate) at two different locations in situ.
  • Patients were given a light dose of 10-17 J cm(-2) at a fluence rate of 45-50 mW cm(-2) based on in situ measured light treatment parameters.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / drug therapy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / drug therapy. Lighting / instrumentation. Photochemotherapy / instrumentation. Photosensitizing Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20230986.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


10. Walts AE, Lechago J, Bose S: P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia. Am J Surg Pathol; 2006 Jul;30(7):795-801
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.
  • HPV is also associated with anal squamous dysplasias and carcinomas.
  • Significant interobserver and intraobserver variation exists in the interpretation of biopsies for anal intraepithelial neoplasia (AIN).
  • This study was undertaken to assess the potential role of p16 and Ki67 immunohistochemical expression in refining the diagnosis and grading of AIN.One-hundred and four anal biopsies from 74 patients were retrieved from the surgical pathology files of the department.
  • After discrepancies were resolved and concurrence was achieved by at least 2 of 3 reviewing pathologists, the diagnoses were as follows: 37 negative, 12 condylomas without overt dysplasia, 14 AIN I, 25 AIN II, and 16 AIN III. p16 and Ki67 expression was evaluated by ABC immunoperoxidase staining whereas the presence of the high-risk subtypes of HPV virus was determined by in situ hybridization on a subset of the biopsies.
  • A band-like pattern of p16 immunoreactivity was seen in 21.4% AIN I, 80% AIN II, and 87.5% AIN III cases.
  • Spotty p16 immunoreactivity was observed in 8.1% negative, 8.3% condyloma, 14.3% AIN I, 12.0% AIN II, and 12.5% AIN III cases.
  • More than 50% of nuclei stained positive for Ki67 in 28.6% AIN I, 48.0% AIN II, and 75.0% AIN III cases but in none of the negative or condyloma cases.
  • On the basis of these results, a band-like pattern of p16 staining and Ki67 positivity in >50% of the squamous cell nuclei were strongly associated with high-grade AIN.
  • Most AIN I lesions stained similar to the nondysplastic cases.
  • A small subset of biopsies studied did not conform to the pattern described above: 4 of 14 (28.6%) AIN I lesions showed a band-like pattern of p16 staining and/or >50% Ki67 positive nuclei.
  • 4 of 25 (16.0%) AIN II lesions comprising 9.8% of the 41 high-grade AINs (AIN II and III) showed spotty p16 positivity and <50% Ki67 positive nuclei.
  • We conclude that when used together and evaluated in conjunction with H&E stained sections, p16 and Ki67 immunoexpression is a useful adjunct in the diagnosis and grading of AIN.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ki-67 Antigen / metabolism. Papillomavirus Infections / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. DNA, Viral / analysis. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Papillomaviridae / genetics. Papillomaviridae / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819320.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Ki-67 Antigen
  •  go-up   go-down


11. Bean SM, Meara RS, Vollmer RT, Conner MG, Crowe DR, Novak L, Eltoum IA, Robboy SJ, Chhieng DC: p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia. J Low Genit Tract Dis; 2009 Jul;13(3):145-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia.
  • OBJECTIVES: Evaluation of anal intraepithelial neoplasia (AIN) is subjective.
  • Previous studies have shown p16 and Ki-67 expressions to correlate with AIN grade.
  • The objectives were (1) to determine the extent of interobserver agreement in evaluating AIN on routine hematoxylin and eosin (H&E) sections and (2) to test whether p16 and/or Ki-67 staining improve interobserver diagnostic agreement.
  • MATERIALS AND METHODS: Seventy-seven anal specimens were retrieved.
  • Diagnoses were normal/reactive, AIN I/HPV, AIN II, and AIN III.
  • Fair agreement was observed using H&E diagnosis alone (kappa = 0.38, S = 0.56).
  • CONCLUSIONS: Interobserver agreement for diagnosis of AIN was fair when based solely on H&E preparation. p16 alone improved interobserver agreement and demonstrated superior agreement when compared with H&E, Ki-67, and H&E/p16/Ki-67 combined.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. DNA, Neoplasm / analysis. Gene Expression Regulation, Neoplastic. Genes, p16 / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Biopsy. Clinical Competence. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Observer Variation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550211.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA, Neoplasm
  •  go-up   go-down


12. Scott H, Khoury J, Moore BA, Weissman S: Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. Sex Transm Dis; 2008 Feb;35(2):197-202
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic.
  • OBJECTIVES: The purpose of this study is to describe our experience with routine anal cancer screening using anal cytology, determine risk factors for abnormal anal cytology, and determine if an association exists between cytology and histology in patients with HIV infection.
  • RESULTS: Overall, 276 of 560 of the clinic patients received a screening anal cytology during the study period.
  • Of these patients, 11 were excluded from the analysis and 74 of 265 (27.9%) patients screened had an abnormal anal cytology.
  • They were also more likely to have a lower CD4+ nadir (142 cells/mm3 vs. 223 cells/mm3, P = 0.005) and CD4+ at time of anal cytology (353 cells/mm3 vs. 497 cells/mm3, P <0.001).
  • Those with an abnormal anal cytology also had higher occurrence of anal disease on perianal visual inspection (30% vs. 9%, P <0.001) and were more likely to have a history of genital warts (23% vs. 12%, P = 0.02) or herpes (35% vs. 22%, P = 0.02).
  • Two patients had anal intraepithelial neoplasia (AIN) I, 2 AIN II, 3 AIN III, and 2 squamous cell carcinoma in situ on histology.
  • CONCLUSION: Routine anal cytology screening is a feasible tool to incorporate into HIV care for patients regardless of gender and HIV risk factors.
  • [MeSH-major] Anus Neoplasms / diagnosis. HIV Infections / complications. Neoplasms, Squamous Cell / pathology. Urban Health Services / organization & administration
  • [MeSH-minor] Adult. Aged. Anal Canal / pathology. Colonoscopy / methods. Female. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216727.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D: HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis; 2006 Mar;21(2):135-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis.
  • BACKGROUND AND AIMS: Majority of cases of anal squamous cell carcinoma are human papilloma virus (HPV)-induced and result from anal intraepithelial neoplasia (AIN).
  • This study was conducted to examine methods which may enable the routine diagnosis of HPV-induced changes in the anal rim and the consequences of such detection especially in view of a more sensitive diagnosis of AIN.
  • METHODS: The study included biopsy samples from 87 patients who had been diagnosed with the following disease patterns: 47 invasive anal carcinoma, 33 AIN of varying severity and seven condylomatous lesions.
  • RESULTS: In 38 of 47 cases of anal carcinoma, HPV DNA could be detected via PCR (80.9%), the majority of which were HPV 16 (33/38=86.8%).
  • In 29 of the 33 cases of AIN, HPV DNA was detected (87.9%), most of these in AIN III (15/16=93.8%).
  • DISCUSSION: In our series, the clinical diagnosis of the invasive anal carcinoma had a high sensitivity of 93.6%, with a specificity of 80%.
  • In contrast, AIN had been detected clinically in none of the cases.
  • In this situation, especially with high-risk patients, our findings recommend anal HPV screening in combination with anal cytology and anoscopy.
  • CONCLUSION: Based on our results, we urgently recommend for any histological report on excision of anal lesions to include a statement whether histological markers of HPV infection were detected.
  • [MeSH-major] Alphapapillomavirus / genetics. Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Colorectal Dis. 2007 Oct;22(10):1289 [16703315.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):57-62 [12589647.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1534-8 [9836490.001]
  • [Cites] Cytopathology. 1998 Feb;9(1):15-22 [9523124.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Sao Paulo Med J. 2003 May 5;121(3):128-32 [12920476.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):203-6 [2166709.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2229-42 [12441259.001]
  • [Cites] Br J Cancer. 1997;76(10):1271-8 [9374370.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]
  • [Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):692-9 [12861066.001]
  • [Cites] J Clin Microbiol. 1990 Dec;28(12):2739-43 [2177751.001]
  • [Cites] J Med Microbiol. 2004 Feb;53(Pt 2):125-8 [14729933.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):173-8 [10067816.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Cytopathology. 2005 Feb;16(1):13-21 [15859310.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]
  • [Cites] Scand J Infect Dis. 1996;28(6):629-32 [9060069.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):345-51 [3568924.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):19-26 [14968414.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Dtsch Med Wochenschr. 2003 Sep 19;128(38):1957-62 [14502448.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):958-67 [7842416.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):113-7 [12704691.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • (PMID = 15864603.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


14. Bean SM, Chhieng DC, Roberson J, Raper JL, Broker TR, Hoesley CJ, Eltoum IA, Jin G: Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients. J Low Genit Tract Dis; 2010 Apr;14(2):90-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients.
  • OBJECTIVES: We describe the cytological distribution of disease, correlate cytological diagnoses with human papillomavirus (HPV) DNA status and surgical biopsy diagnoses, determine if CD4 counts correlate with lesion severity, and compare anal-rectal data of HIV-infected patients (primarily men) with cervical data.
  • MATERIALS AND METHODS: A retrospective search of the computerized database identified 118 HIV-positive patients who had anal-rectal cytology.
  • Cytology results were compared with available follow-up data including repeat anal-rectal cytology tests, surgical biopsy, CD4 counts, and HPV DNA polymerase chain reaction-based genotyping.
  • RESULTS: Cytological diagnoses included 3% unsatisfactory for diagnosis, 41% negative for intraepithelial lesion or malignancy (NILM), 23% atypical squamous cells of undermined significance (ASC-US), 31% low-grade squamous intraepithelial lesion (LSIL), and 2% high-grade squamous intraepithelial lesion (HSIL) (ASC-US/squamous intraepithelial lesion, 0.7:1).
  • Two anal intraepithelial neoplasia (AIN) II, 10 AIN III, and 1 invasive squamous cell carcinoma were histologically detected (11%).
  • The majority of AIN II was preceded by LSIL, 54%; ASC-US, 15%; and HSIL, 8%.
  • CONCLUSIONS: Anal-rectal cytology is a useful screening test.
  • A high percentage of AIN II lesions were detected in this at-risk population, and the majority was detected following cytological abnormality.
  • [MeSH-major] Anal Canal / pathology. HIV Infections / complications. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Rectal Neoplasms / epidemiology. Rectum / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354415.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83679
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Staniek H, Krejpcio Z: The effects of tricentric chromium(III) propionate complex supplementation on pregnancy outcome and maternal and foetal mineral status in rat. Food Chem Toxicol; 2009 Oct;47(10):2673-8
Hazardous Substances Data Bank. PROPIONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of tricentric chromium(III) propionate complex supplementation on pregnancy outcome and maternal and foetal mineral status in rat.
  • Chromium(III) is an essential element for carbohydrate and lipid metabolism, and various chemical forms of this element are widely used as dietary supplements.
  • Female Wistar rats (n=20, 14 weeks old) were mated with males and, after successful conception were fed either AIN-93G diet supplemented with CrProp (100mg Cr/kg diet, equals to 7.2mg Cr/kg body mass/day) or non-supplemented diet (0.27 mg Cr/kg diet, equals to 0.02 mg Cr/kg body mass/day) for 21 days.

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • Hazardous Substances Data Bank. ZINC PROPIONATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19651186.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Micronutrients; 0 / Propionates; 0 / Trace Elements; 79-09-4 / propionic acid
  •  go-up   go-down


16. Rizk DE, Hassan HA, Al-Marzouqi AH, Ramadan GA, Al-Kedrah SS, Daoud SA, Fahim MA: Combined estrogen and ghrelin administration restores number of blood vessels and collagen type I/III ratio in the urethral and anal canal submucosa of old ovariectomized rats. Int Urogynecol J Pelvic Floor Dysfunct; 2008 Apr;19(4):547-52
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined estrogen and ghrelin administration restores number of blood vessels and collagen type I/III ratio in the urethral and anal canal submucosa of old ovariectomized rats.
  • We compare the effects of estrogen and/or ghrelin on vascular counts and collagen I/III ratio of urethral and anal canal submucosa in old vs young-adult ovariectomized rats.
  • Blood vessel counts and collagen I/III ratio were measured, respectively, by light microscopy and Western blot analysis with immunohistochemistry of ghrelin receptors.
  • Estrogen significantly increased urethral and anal vascular counts and collagen I/III ratio in young-adult rats.
  • Ghrelin receptors were immunostained in urethral and anal submucosa of all samples.
  • Combined estrogen/ghrelin administration restored postovariectomy urethral and anal canal submucosal vessel number and collagen I/III ratio in old rats suggesting independent ageing effect.
  • [MeSH-major] Anal Canal / blood supply. Collagen Type I / metabolism. Collagen Type III / metabolism. Estradiol / administration & dosage. Ghrelin / administration & dosage. Neovascularization, Physiologic / drug effects. Ovariectomy. Urethra / blood supply

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Res. 2004 Nov-Dec;53(6 Suppl):S1-10 [15586141.001]
  • [Cites] Nature. 2000 Oct 19;407(6806):908-13 [11057670.001]
  • [Cites] Br J Nutr. 2006 Aug;96(2):201-26 [16923214.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep;17(5):541-5 [16538421.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2007 Apr;18(4):413-8 [16900438.001]
  • [Cites] Orv Hetil. 2006 Mar 12;147(10):441-8 [16573173.001]
  • [Cites] J Bone Miner Res. 2005 May;20(5):790-8 [15824852.001]
  • [Cites] J Neuroendocrinol. 2006 Jan;18(1):65-76 [16451222.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):80-8 [16932262.001]
  • [Cites] Physiol Behav. 2007 Dec 5;92(5):911-23 [17675121.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Sep;17 (5):472-7 [16520891.001]
  • [Cites] J Am Geriatr Soc. 2006 Mar;54(3):405-12 [16551306.001]
  • [Cites] Mayo Clin Proc. 2006 May;81(5):653-60 [16706263.001]
  • [Cites] J Physiol. 2006 May 15;573(Pt 1):251-62 [16543266.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 2):S11-5 [16458733.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2007 Sep;18(9):1077-85 [17205219.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3559-65 [16804038.001]
  • [Cites] Urol Res. 2003 Jul;31(3):147-51 [12669156.001]
  • [Cites] Obstet Gynecol. 2005 Nov;106(5 Pt 1):940-5 [16260510.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jun;17(4):407-17 [16572280.001]
  • [Cites] J Pharmacol Sci. 2006;100(5):398-410 [16612045.001]
  • [Cites] Urology. 2005 Dec;66(6):1343-8 [16360481.001]
  • [Cites] Fertil Steril. 2006 Jun;85(6):1563-81 [16759918.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):481-7 [15521940.001]
  • [Cites] JAMA. 2005 Feb 23;293(8):935-48 [15728164.001]
  • [Cites] Nat Neurosci. 2006 Mar;9(3):381-8 [16491079.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Feb 9;353(2):238-43 [17184731.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):620-7 [15041990.001]
  • (PMID = 17876488.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type III; 0 / Ghrelin; 4TI98Z838E / Estradiol
  •  go-up   go-down


17. Alves CC, Torrinhas RS, Giorgi R, Brentani MM, Logullo AF, Arias V, Mauad T, da Silva LF, Waitzberg DL: Short-term specialized enteral diet fails to attenuate malnutrition impairment of experimental open wound acute healing. Nutrition; 2010 Sep;26(9):873-9
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Control rats received a standard oral diet (AIN-93M chow) plus enteral saline solution.
  • On post-trauma days 7 and 14, wound granulation tissue samples were collected for morphologic analysis using hematoxylin and eosin and picrosirius stain or immunohistochemistry slides and real-time polymerase chain reaction for collagen I and III gene expression.
  • RESULTS: Malnourished control rats had increased intensity and duration of wound inflammation, impaired increase of fibroblast cells contingent on post-trauma days 7 to 14, decreased expression of collagen III, and less wound contraction compared with eutrophic control rats.
  • [MeSH-major] Antioxidants / therapeutic use. Arginine / therapeutic use. Malnutrition / complications. Skin / pathology. Wound Healing / physiology. Wounds, Penetrating / diet therapy

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20692600.001).
  • [ISSN] 1873-1244
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 9007-34-5 / Collagen; 94ZLA3W45F / Arginine
  •  go-up   go-down


18. Al-Otaiba A, John A, Al-Belooshi T, Raza H: Redox homeostasis and respiratory metabolism in camels (Camelus dromedaries): comparisons with domestic goats and laboratory rats and mice. J Comp Physiol B; 2010 Nov;180(8):1121-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mitochondria isolated from the tissues of these animals showed a comparable ability to metabolize specific substrates for respiratory enzyme complexes I, II/III and IV.
  • On the other hand, complex II/III activity in camel kidney was higher compared to the other species.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24680-9 [11325963.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Oct 15;216(2):309-18 [16843508.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:143-83 [17029566.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18960-70 [12646569.001]
  • [Cites] Biochem J. 2002 Aug 15;366(Pt 1):45-55 [12020353.001]
  • [Cites] Mol Aspects Med. 2009 Feb-Apr;30(1-2):29-41 [18786561.001]
  • [Cites] J Biol Chem. 2009 Jun 12;284(24):16236-45 [19366681.001]
  • [Cites] Vet Hum Toxicol. 1999 Feb;41(1):35-8 [9949485.001]
  • [Cites] Comp Biochem Physiol C. 1993 Jan;104(1):137-45 [8097448.001]
  • [Cites] Chem Biol Interact. 2006 Oct 27;163(1-2):54-67 [16600197.001]
  • [Cites] Trends Endocrinol Metab. 2009 Sep;20(7):332-40 [19733481.001]
  • [Cites] Free Radic Biol Med. 2004 Sep 15;37(6):755-67 [15304252.001]
  • [Cites] Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):205-11 [9972462.001]
  • [Cites] Methods Cell Biol. 2001;65:97-117 [11381612.001]
  • [Cites] Mitochondrion. 2005 Oct;5(5):303-21 [16150655.001]
  • [Cites] Diabetes. 2004 Jan;53(1):185-94 [14693714.001]
  • [Cites] Antioxid Redox Signal. 2009 Nov;11(11):2685-700 [19558212.001]
  • [Cites] Reprod Biol. 2005 Mar;5(1):5-17 [15821775.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49064-73 [15317809.001]
  • [Cites] Comp Biochem Physiol Pharmacol Toxicol Endocrinol. 1994 Mar;107(3):379-86 [8061945.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Jan 15;226(2):161-8 [17935746.001]
  • [Cites] J Biol Chem. 2006 Jan 27;281(4):2061-70 [16303765.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2459-66 [17237252.001]
  • [Cites] Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17 [16829228.001]
  • [Cites] Apoptosis. 2009 Apr;14(4):624-40 [19205885.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S3-6 [16958667.001]
  • [Cites] Mol Interv. 2005 Apr;5(2):94-111 [15821158.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2004 Dec;139(4):289-93 [15683840.001]
  • [Cites] Biochem J. 2009 May 27;420(3):439-49 [19338496.001]
  • [Cites] Trends Pharmacol Sci. 2006 Dec;27(12):639-45 [17056127.001]
  • [Cites] Cell Immunol. 2007 May;247(1):12-7 [17716639.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 May 1;204(3):263-73 [15845418.001]
  • [Cites] Vet Res Commun. 2000 May;24(4):245-60 [10836270.001]
  • (PMID = 20532892.001).
  • [ISSN] 1432-136X
  • [Journal-full-title] Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology
  • [ISO-abbreviation] J. Comp. Physiol. B, Biochem. Syst. Environ. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Electron Transport Chain Complex Proteins; 0 / Reactive Oxygen Species; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 2.5.1.18 / Glutathione Transferase; GAN16C9B8O / Glutathione
  •  go-up   go-down


19. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A: Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol; 2005 Nov;100(11):2447-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
  • Group III comprised 70 patients who received induction-dose triple therapy (IDTT) in the form of IFN-alpha2b 3 MU once daily for the first 4 wks then reduced to TIW for 20 wks plus RBV 1,000-1,200 mg per day based on body weight and AMD 100 mg twice daily for 24 wks.
  • Six patients from group I, eight patients from group II, and four from group III discontinued the study either due to financial limitations and/or intolerable adverse effects of the drugs.
  • RESULTS: Intention-to-treat analysis revealed that sustained virological response (SVR) achieved in 22 (55.0%), 34 (48.6%), and 20 (28.6%) in groups I, II, and III, respectively.
  • Adherence-to-treatment analysis (80/80/80) revealed that SVR achieved in 22 (64.7%), 34 (54.8%), and 20 (30.3%) in groups I, II, and III, respectively.

  • Genetic Alliance. consumer health - Hepatitis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • Hazardous Substances Data Bank. AMANTADINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279899.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Drug Carriers; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b; BF4C9Z1J53 / Amantadine
  •  go-up   go-down


20. Attia AS: Synthesis and spectroscopic studies on chromium(III) complex containing mixed-valence chrysenesemiquinone-chrysenecatecholate ligands and 2,2'-bipyridine coligand. Spectrochim Acta A Mol Biomol Spectrosc; 2007 Aug;67(5):1339-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and spectroscopic studies on chromium(III) complex containing mixed-valence chrysenesemiquinone-chrysenecatecholate ligands and 2,2'-bipyridine coligand.
  • The synthesis and spectroscopic properties of Cr(bpy)(chrySQ)(chryCat), a complex containing chromium(III) metal ion and chrysenequinone ligand in its partially reduced (chrySQ) and fully reduced (chryCat) forms, are described.
  • Variable temperature magnetic susceptibility measurements indicated a strong antiferromagnetic coupling between Cr(III) (S=3/2) and chrysenesemiquinone radical (S=1/2), giving a magnetic coupling constant J=-342 cm(-1).

  • Hazardous Substances Data Bank. 2,2'-BIPYRIDINE .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126590.001).
  • [ISSN] 1386-1425
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catechols; 0 / Chrysenes; 0 / Ligands; 0 / Organometallic Compounds; 0R0008Q3JB / Chromium; 551W113ZEP / 2,2'-Dipyridyl
  •  go-up   go-down


21. Król E, Krejpcio Z: Chromium(III) propionate complex supplementation improves carbohydrate metabolism in insulin-resistance rat model. Food Chem Toxicol; 2010 Oct;48(10):2791-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromium(III) propionate complex supplementation improves carbohydrate metabolism in insulin-resistance rat model.
  • The purpose of this study was to evaluate the antidiabetic potential and safety of the chromium(III) propionate complex (CrProp) in insulin resistance induced by a high-fructose diet in rats.
  • Animals were fed at libitum: the control diet (AIN-93M), and high-fructose diets (HF) containing various levels of Cr(III) given as CrProp (1 mg Cr kg(-1) diet (HF) and supplemented with 10 mg Cr kg(-1) diet (HFCr10), or 50 mg Cr kg(-1) diet (HFCr50), equal to approx.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ZINC PROPIONATE .
  • Hazardous Substances Data Bank. PROPIONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20633590.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Metals; 0 / Propionates; 30237-26-4 / Fructose; 79-09-4 / propionic acid
  •  go-up   go-down


22. Iman SS, El-Sahrigy S, Sedki M, Baker S, Marey S: Role of protein Z and protein C in neonates with respiratory distress syndrome in Egypt (experience of one centre). Pak J Biol Sci; 2009 Nov 15;12(22):1468-73
Genetic Alliance. consumer health - C Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of protein Z and protein C in neonates with respiratory distress syndrome in Egypt (experience of one centre).
  • Sixty newborn infants, recruited from the neonatal unit, were enrolled in the study and divided into 3 groups: Group (I): 20 preterm with RDS, Group (II): 20 healthy preterm control newborns (CPT) and Group (III): 20 healthy full term control newborns (CFT).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180321.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Protein C; 0 / plasma protein Z
  •  go-up   go-down


23. Shebl M: Synthesis, spectral and magnetic studies of mono- and bi-nuclear metal complexes of a new bis(tridentate NO2) Schiff base ligand derived from 4,6-diacetylresorcinol and ethanolamine. Spectrochim Acta A Mol Biomol Spectrosc; 2009 Jul 15;73(2):313-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ligand reacted with iron(III), cobalt(II), nickel(II), copper(II), zinc(II), cadmium(II), cerium(III) and uranyl(VI) ions, in absence and in presence of LiOH, to yield mono- and bi-nuclear complexes with different coordinating sites.

  • Hazardous Substances Data Bank. Nitrogen dioxide .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345138.001).
  • [ISSN] 1386-1425
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4,6-diacetylresorcinol; 0 / Ethanolamines; 0 / Ligands; 0 / Metals; 0 / Resorcinols; 0 / Schiff Bases; S7G510RUBH / Nitrogen Dioxide
  •  go-up   go-down


24. Inomata S, Watanabe A, Nomura M, Ando T: Mating communication systems of four Plusiinae species distributed in Japan: identification of the sex pheromones and field evaluation. J Chem Ecol; 2005 Jun;31(6):1429-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sex pheromones of four Plusiinae species in the family Noctuidae, Ctenoplusia albostriata (CA), Macdunnoughia purissima (MP), Syngrapha ain (SA), and Diachrysia stenochrysis (DS) were identified by GC-EAD and GC-MS analyses.
  • CA females produced (Z)-5-decenyl acetate (I), (Z)-7-dodecenyl acetate (II), and (Z)-7-dodecen-1-ol (III) in a ratio of 2:100:13.
  • While the antennae of CA males responded to all three components, neither I nor III was essential to capture males.
  • The MP females produced II, III, and (Z)-5-dodecenyl acetate (IV) in a ratio of 100:80:20, and this blend captured the most MP males.
  • Compounds II and III were also identified from SA females, and mixtures ranging from 4:1 to 2:3 were equally attractive to males.
  • DS females only produced one active compound, (Z)-7-decenyl acetate (V), and DS is the first Plusiinae species identified as using only the omega3-compound and none of omega5-compounds, such as II and III, which are common components of Plusiinae pheromones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222781.001).
  • [ISSN] 0098-0331
  • [Journal-full-title] Journal of chemical ecology
  • [ISO-abbreviation] J. Chem. Ecol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 7-dodecen-1-ol; 0 / 7-dodecenyl acetate; 0 / Acetates; 0 / Pheromones; 0 / Sex Attractants; 38421-90-8 / 5-decenyl acetate
  •  go-up   go-down


25. Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K, Reddy GB: Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci; 2005 Jun;46(6):2092-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group I and II animals received an unsupplemented AIN-93 diet, and those in groups III, IV, and V received 0.002% and 0.01% curcumin and 0.5% turmeric, respectively, in an AIN-93 diet for a period of 8 weeks.

  • MedlinePlus Health Information. consumer health - Cataract.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914628.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Crystallins; 0 / Insulin; 0 / Thiobarbituric Acid Reactive Substances; EC 1.- / Oxidoreductases; GAN16C9B8O / Glutathione; IT942ZTH98 / Curcumin
  •  go-up   go-down


26. Abdel-Shafi AA, Bourdelande JL, Ali SS: Photosensitized generation of singlet oxygen from rhenium(I) and iridium(III) complexes. Dalton Trans; 2007 Jun 28;(24):2510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photosensitized generation of singlet oxygen from rhenium(I) and iridium(III) complexes.
  • Photophysical properties in dilute acetonitrile solution are reported for a number of iridium(III) and rhenium(I) complexes.
  • Efficiency of singlet oxygen production, f(Delta)(T), following oxygen quenching of the lowest excited states of these complexes, are in the range of 0.27-1.00.
  • The rate constants and the efficiency of singlet oxygen formation are quantitatively reproduced by a model that assumes the competition between a non-charge transfer (nCT) and a CT deactivation channel.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563786.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. El-Folly RF, El-Kabarity RH, Arafa NA: Assessment of the role of interleukin-6 in diagnosis of hepatocellular carcinoma. Egypt J Immunol; 2010;17(2):11-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the role of interleukin-6 in diagnosis of hepatocellular carcinoma.
  • Interleukin-6 (IL-6) is a promising tumor marker for hepatocellular carcinoma; HCC.
  • This study assesses the value of measuring serum level of interleukin-6 in patients with chronic liver disease and HCC, and evaluates its sensitivity and specificity in comparison to AFP in early diagnosis of HCC.
  • Group II: 25 patients with HCC on top of post-viral hepatitic with elevation in AFP (> 200 ng); and Group III: 25 patients with HCC on top of post-viral hepatitic but without elevation in AFP (< 200 ng).
  • Combining the two markers can provide a new perspective in the diagnosis of HCC.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23082483.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / alpha-Fetoproteins
  •  go-up   go-down


28. Fathy MM, Asaad A, Mansour M, El-Said H, El-Haddad OK: Cellular interferon-gamma based assay for diagnosis of pulmonary tuberculosis. Egypt J Immunol; 2007;14(1):33-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular interferon-gamma based assay for diagnosis of pulmonary tuberculosis.
  • This study aimed at evaluating the diagnostic potential of IFN-gamma in vitro production assay for diagnosis of pulmonary tuberculosis.
  • Thirty patients had the provisional clinical and radiological diagnosis of pulmonary tuberculosis (TB), twenty of them had positive acid fast (AF) sputum smears (group I), and ten had negative smears (group II).
  • Ten patients with non tuberculous chest diseases were also included as a control group (group III).
  • Based on bacteriological diagnosis as the gold standard for diagnosis of pulmonary TB, the specificity of the assay was found to be 75%.
  • However the assay results were negative in all non tuberculous patients (group III).

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689279.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / CFP-10 protein (71-85), Mycobacterium tuberculosis; 0 / ESAT-6 protein, Mycobacterium tuberculosis; 0 / Peptide Fragments; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


29. Abouzid K, Abdel Hakeem M, Khalil O, Maklad Y: Pyridazinone derivatives: design, synthesis, and in vitro vasorelaxant activity. Bioorg Med Chem; 2008 Jan 1;16(1):382-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an attempt to identify potential vasodilator-cardiotonic lead compounds, three series of pyridazinones were designed using three-dimensional pharmacophore developed with CATALYST software from a set of potent cyclic nucleotide phosphodiesterase III, cAMP PDEIII inhibitors.
  • The features of the target compounds were based on the structures of many biologically active lead compounds with cAMP phosphodiesterase III inhibiting activity such as Milrinone and others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905589.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Enzyme Inhibitors; 0 / Phosphodiesterase 3 Inhibitors; 0 / Pyridazines; 0 / Vasodilator Agents
  •  go-up   go-down


30. Abdel-Hameed DM, Hassanein OM: Genotyping of Toxoplasma gondii strains from female patients with toxoplasmosis. J Egypt Soc Parasitol; 2008 Aug;38(2):511-20
MedlinePlus Health Information. consumer health - Toxoplasmosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-eight female patients with abortion and intrauterine fetal death were selected from the Obstetric and Gynecology Emergency, Ain Shams University Hospitals, with positive PCR results for toxoplasmosis in previous study.
  • Type III was determined by resistance of the 3' end nested-PCR products of SAG2 locus to cleavage by Sau3AI.
  • Type I was found in 5 (13%) of the isolates, whereas genotype III was not never found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853624.001).
  • [ISSN] 1110-0583
  • [Journal-full-title] Journal of the Egyptian Society of Parasitology
  • [ISO-abbreviation] J Egypt Soc Parasitol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Protozoan; 0 / DNA, Protozoan; 0 / Protozoan Proteins; 133134-61-9 / surface antigen P22, Toxoplasma
  •  go-up   go-down


31. Tantawy AA, Adly AA, El Maaty MG, Amin SA: Subclinical atherosclerosis in young beta-thalassemia major patients. Hemoglobin; 2009;33(6):463-74
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety subjects were included and divided into three groups: group I comprised 30 beta-TM patients with a mean age of 18.4 +/- 6.18 years; group II comprised of 30 type 1 diabetic patients with a mean age of 19.23 +/- 4.25 years, and 30 healthy subjects served as controls in group III.


32. Hassan SS, Hamza MS, Kelany AE: A novel spectrophotometric method for batch and flow injection determination of cyanide in electroplating wastewater. Talanta; 2007 Feb 28;71(3):1088-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The method is used in static mode for determining cyanide over the concentration range 0.04-1.20mugml(-1) with a detection limit of 0.02mugml(-1) and for hydrodynamic analysis of 0.4-5.2mugml(-1) cyanide.
  • (iii) good solubility and stability of the reagent in aqueous solutions over a wide pH range;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071417.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Elwakil HS, Ali NM, Talaat RM, Osman WM: Impact of experimental duel infections with Schistosoma mansoni and Echinoccocus granulosus on hepatic histopathology. J Egypt Soc Parasitol; 2007 Dec;37(3 Suppl):1175-88
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of the significant increase of NO level when E. granulosus infection induced in late stages of schistosomisais (GsII & III), yet granuloma size was not suppressed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431992.001).
  • [ISSN] 1110-0583
  • [Journal-full-title] Journal of the Egyptian Society of Parasitology
  • [ISO-abbreviation] J Egypt Soc Parasitol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


34. Rozmus-Warcholińska W, Loch T, Czuba B, Mazurek U, Mucha J, Dworak D, Sodowski K: [Genital warts associated with HPV infection during II and III trimester of pregnancy--a case report and analysis of treatment options]. Ginekol Pol; 2007 Nov;78(11):888-91
MedlinePlus Health Information. consumer health - Infections and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genital warts associated with HPV infection during II and III trimester of pregnancy--a case report and analysis of treatment options].
  • [Transliterated title] Kłykciny kończyste u ciezarnej w II i III trymestrze ciazy--opis sytuacji klinicznej i analiza zastosowanego leczenia.
  • A visible genital form of HPV infection are genital warts, which are commonly caused by HPV types 6 and 11, and appear on the vulva, cervix, vagina, urethra and anus.
  • Oncogenic HPV types 16, 18, 31, 33 and 35 are also found in genital warts and are associated with vulval (VII), cervical (CIN) and anal (AIN) intraepithelial neoplasia.
  • In the paper a case report on genital warts associated with HPV infection during II and III trimester of pregnancy and analysis of treatment options has been presented.
  • [MeSH-major] Condylomata Acuminata / diagnosis. Condylomata Acuminata / therapy. Human papillomavirus 6 / isolation & purification. Pregnancy Complications, Infectious / diagnosis. Pregnancy Complications, Infectious / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306923.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


35. Saadi H, Al-Kaabi J, Benbarka M, Khalili A, Almahmeed W, Nagelkerke N, Abdel-Wareth L, Al Essa A, Yasin J, Al-Dabbagh B, Kazam E: Prevalence of undiagnosed diabetes and quality of care in diabetic patients followed at primary and tertiary clinics in Abu Dhabi, United Arab Emirates. Rev Diabet Stud; 2010;7(4):293-302
MedlinePlus Health Information. consumer health - Diabetes Type 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of undiagnosed diabetes and quality of care in diabetic patients followed at primary and tertiary clinics in Abu Dhabi, United Arab Emirates.
  • AIMS: To investigate the prevalence of undiagnosed type 2 diabetes (T2D) at primary health care (PHC) clinics, and to assess the quality of care of diabetic patients followed at a tertiary hospital diabetes center in Abu Dhabi, United Arab Emirates (UAE).
  • METHODS: Between May 2009 and October 2010, adult patients attending two PHC clinics, and adult diabetic patients attending the diabetes center, were invited to participate in the study.
  • After overnight fast, participants returned for interview and laboratory tests.
  • Undiagnosed T2D was defined by FPG ≥ 7.0 mmol/l or HbA1c ≥ 6.5%.
  • Quality of care was assessed by reported care practices and achievement of internationally recognized targets.
  • RESULTS: Out of 239 patients at PHC clinics without history of T2D, 14.6% had undiagnosed T2D, and 31% had increased risk of diabetes (FPG 5.6-7.0 mmol/l or HbA1c 5.7-6.5%).
  • The independent predictors of undiagnosed T2D were age (adjusted OR per year 1.07, 95% CI 1.04-1.11, p < 0.001) and BMI ≥ 25 (adjusted OR 4.2, 95% CI 0.91-19.7, p = 0.033).
  • Amongst all 275 diagnosed T2D patients, including those attending PHC clinics and those followed at the diabetes center, it was found that 40.1% followed dietary recommendations, 12% reported visiting a diabetes educator, 28.2% walked for exercise, and 13.5% attained recognized targets of HbA1c < 7%, blood pressure < 130/80 mmHg, and LDL cholesterol < 2.6 mmol/l.
  • CONCLUSIONS: Almost half of the adult patients attending PHC clinics had undiagnosed T2D, or increased diabetes risk.
  • Care practices, and achievement of treatment targets, were suboptimal.
  • [MeSH-major] Diabetes Mellitus, Type 2 / epidemiology. Primary Health Care
  • [MeSH-minor] Adult. Ambulatory Care Facilities. Blood Pressure / physiology. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. United Arab Emirates / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Diabet Stud. 2010 Spring;7(1):26-35 [20703436.001]
  • [Cites] Prog Cardiovasc Dis. 2010 Jul-Aug;53(1):28-38 [20620423.001]
  • [Cites] Diabetes Care. 2010 Oct;33(10):2146-51 [20664020.001]
  • [Cites] BMC Public Health. 2010;10:679 [21059202.001]
  • [Cites] Diabetes Care. 2011 Jan;34 Suppl 1:S11-61 [21193625.001]
  • [Cites] CMAJ. 2011 Feb 8;183(2):E115-27 [21149524.001]
  • [Cites] Diabetes Care. 2000 Jun;23(6):750-3 [10840990.001]
  • [Cites] Am J Clin Nutr. 2000 Sep;72(3):694-701 [10966886.001]
  • [Cites] N Engl J Med. 2001 May 3;344(18):1343-50 [11333990.001]
  • [Cites] Diabetes Care. 2001 Oct;24(10):1821-33 [11574449.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):393-403 [11832527.001]
  • [Cites] Diabet Med. 2002 Nov;19(11):962-5 [12421436.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):977-86 [8366922.001]
  • [Cites] BMJ. 1994 Jul 2;309(6946):23-7 [8044063.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):837-53 [9742976.001]
  • [Cites] Diabetologia. 1998 Sep;41(9):1010-6 [9754818.001]
  • [Cites] Diabetes Care. 2005 Jul;28(7):1813-6 [15983346.001]
  • [Cites] Diabetes Res Clin Pract. 2005 Aug;69(2):188-95 [16005369.001]
  • [Cites] Ann Intern Med. 2005 Sep 20;143(6):427-38 [16172441.001]
  • [Cites] Diabet Med. 2006 Jun;23(6):579-93 [16759299.001]
  • [Cites] JAMA. 2006 Jul 26;296(4):427-40 [16868301.001]
  • [Cites] J Hypertens. 2006 Aug;24(8):1449-56 [16877944.001]
  • [Cites] Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125 [17462167.001]
  • [Cites] Diabetes Res Clin Pract. 2007 Dec;78(3):369-77 [17532085.001]
  • [Cites] N Engl J Med. 2008 Feb 7;358(6):580-91 [18256393.001]
  • [Cites] Health Technol Assess. 2008 Apr;12(9):1-116, iii [18405469.001]
  • [Cites] N Engl J Med. 2008 Oct 9;359(15):1577-89 [18784090.001]
  • [Cites] Diabetes Care. 2008 Dec;31(12):2238-43 [18809622.001]
  • [Cites] Br J Gen Pract. 2009 Jan;59(558):43-8 [19105915.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(1):CD005268 [19160249.001]
  • [Cites] Diabetes Care. 2009 Feb;32(2):227-33 [19033410.001]
  • [Cites] Am J Med. 2009 May;122(5):443-53 [19375554.001]
  • [Cites] Public Health Nutr. 2010 Jun;13(6A):993-9 [20513271.001]
  • [Cites] Asia Pac J Public Health. 2010 Jul;22(3 Suppl):54S-59S [20566534.001]
  • [Cites] BMJ. 2010;341:c4093 [20729270.001]
  • (PMID = 21713317.001).
  • [ISSN] 1614-0575
  • [Journal-full-title] The review of diabetic studies : RDS
  • [ISO-abbreviation] Rev Diabet Stud
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3143544
  •  go-up   go-down


36. Amer MS, Wahba HM, Ashmawi SS, Mabrouk RR, Sharaf Eldeen AA, Hamza SA: Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease. Lung India; 2010 Oct;27(4):225-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTINGS AND DESIGN: A case control study involving 90 elderly participants from the outpatient clinics of Ain Shams University hospitals.
  • MATERIALS AND METHODS: The 90 subjects were subdivided into three equal groups ' group I (control), group II (patients with COPD), and group III (patients with COPD and cardiovascular complications).
  • Positive significant correlation between CRP and TNF-α with stage of COPD according to FEV1 (P <0.05) were found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1980 Oct;66(4):859-62 [6903189.001]
  • [Cites] Immun Ageing. 2006;3:3 [16571118.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Feb;163(2):420-2 [11179116.001]
  • [Cites] Eur Respir J. 2003 Feb;21(2):347-60 [12608452.001]
  • [Cites] BMC Cardiovasc Disord. 2004 Oct 14;4:17 [15485576.001]
  • [Cites] Semin Respir Crit Care Med. 2005 Apr;26(2):142-53 [16088433.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55 [17507545.001]
  • [Cites] Chest. 2006 Aug;130(2):326-33 [16899829.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Aug 15;164(4):709-13 [11520741.001]
  • [Cites] Thorax. 2001 Nov;56(11):863-6 [11641511.001]
  • [Cites] Chest. 2002 May;121(5 Suppl):209S-218S [12010854.001]
  • [Cites] Thorax. 2002 Jun;57(6):563-4; author reply 564 [12037238.001]
  • [Cites] Am J Med. 2003 Jun 15;114(9):758-62 [12829203.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L492-9 [12851215.001]
  • [Cites] Chest. 2005 Feb;127(2):558-64 [15705996.001]
  • [Cites] Chest. 2005 Oct;128(4):2099-107 [16236861.001]
  • [Cites] Thorax. 2006 Jan;61(1):10-6 [16284220.001]
  • [Cites] Circulation. 1999 Jul 6;100(1):96-102 [10393687.001]
  • (PMID = 21139720.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2988174
  • [Keywords] NOTNLM ; C-reactive protein / Chronic obstructive pulmonary disease / cytokines / interleukin-1 beta / tumor necrosis factor-α
  •  go-up   go-down


37. Mukhopadhyay S, Guillory B, Mukherjee S, Das SK: Antiproliferative effect of peripheral benzodiazepine receptor antagonist PK11195 in rat mammary tumor cells. Mol Cell Biochem; 2010 Jul;340(1-2):203-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast tumors were induced by administration of a carcinogen, dimethylbenz[a]anthracene to 50-day-old female rats maintained on a standard AIN-76A diet with casein as the protein source.
  • The tumors were of grade I (20%), grade II (60%), and grade III (20%).
  • These cells expressed elevated levels of PBR, a cancer promoting gene.
  • Thus, PBR antagonist may be a potential therapeutic agent for the control of aggressiveness of breast cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 4-CHLORODIAZEPAM .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204676.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Benzodiazepinones; 0 / Carrier Proteins; 0 / GABA-A Receptor Agonists; 0 / GABA-A Receptor Antagonists; 0 / Isoquinolines; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, GABA-A; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, rat; 141440-82-6 / Tspo protein, rat; 14439-61-3 / 4'-chlorodiazepam; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 85340-56-3 / PK 11195
  •  go-up   go-down


38. Itano O, Yang K, Fan K, Kurihara N, Shinozaki H, Abe S, Jin B, Gravaghi C, Edelmann W, Augenlicht L, Kopelovich L, Kucherlapati R, Lamprecht S, Lipkin M: Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis; 2009 Nov;30(11):1923-6
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that sulindac, a non-steroidal anti-inflammatory drug, inhibited tumor formation in the small intestine but increased tumors in the colon of Apc(Min/+) mice, a model of human familial adenomatous polyposis.
  • (ii) Mlh1(+/-) mouse (DNA mismatch repair deficiency, a mouse model of human hereditary non-polyposis colorectal cancer) and (iii) double-heterozygous Mlh1(+/-)Apc(1638N/+) mutant mouse.
  • Mice were fed AIN-76A control diet with or without 0.02% sulindac for 6 months.
  • (iii) sulindac increased tumors in the cecum of all mice regardless of genetic background;.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 2006;73 Suppl 1:136-50 [16498262.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):25-34 [16049979.001]
  • [Cites] Apoptosis. 2007 Jan;12(1):195-209 [17136320.001]
  • [Cites] Histol Histopathol. 2007 Apr;22(4):437-42 [17290354.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1358-75 [17481747.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6B):3807-12 [18225536.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):32-8 [18841250.001]
  • [Cites] J Gastroenterol. 2009;44 Suppl 19:23-9 [19148789.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):93-100 [18952595.001]
  • [Cites] Methods Mol Biol. 2009;511:193-233 [19347299.001]
  • [Cites] Gut. 1999 Dec;45(6):822-8 [10562579.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1407-16 [11729120.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] Curr Opin Cell Biol. 2009 Apr;21(2):317-24 [19217767.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1073-81 [19468060.001]
  • [Cites] J Gastroenterol. 2009;44(9):879-88 [19568687.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):15-20 [10861602.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):605-11 [12663524.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):276-85 [12671666.001]
  • [Cites] Nat Rev Drug Discov. 2003 Sep;2(9):717-26 [12951578.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):372-7 [15251131.001]
  • [Cites] Gastroenterology. 1991 Sep;101(3):635-9 [1650315.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Gastroenterology. 1993 Jun;104(6):1832-47 [8500743.001]
  • [Cites] Br J Surg. 1993 Dec;80(12):1618-9 [8298943.001]
  • [Cites] Gastroenterology. 1994 Sep;107(3):854-7 [8076772.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):936-8 [7842414.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):813-30 [7634976.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Gut. 1996 Apr;38(4):578-81 [8707091.001]
  • [Cites] Carcinogenesis. 1996 Aug;17(8):1757-60 [8761438.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Am J Gastroenterol. 1998 Nov;93(11):2261-6 [9820411.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1301-7 [10096563.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):51-9 [15657353.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5248-56 [16033843.001]
  • [Cites] Surgery. 2006 Jun;139(6):782-8 [16782435.001]
  • (PMID = 19755659.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-15116; United States / NCI NIH HHS / CN / N01-CN-43308; United States / NCI NIH HHS / CA / R01 CA 87559
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Mlh1 protein, mouse; 0 / Nuclear Proteins; 184SNS8VUH / Sulindac
  • [Other-IDs] NLM/ PMC2783002
  •  go-up   go-down


39. Amin A, Mahmoud-Ghoneim D: Zizyphus spina-christi protects against carbon tetrachloride-induced liver fibrosis in rats. Food Chem Toxicol; 2009 Aug;47(8):2111-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, ZSC reduced the expression of alpha-smooth muscle actin, the deposition of types I and III collagen in CCl(4)-injured rats.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500642.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Plant Extracts; 0 / Proteins; 9007-34-5 / Collagen; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


40. Bouaziz M, Bahloul M, Kallel H, Samet M, Ksibi H, Dammak H, Ahmed MN, Chtara K, Chelly H, Hamida CB, Rekik N: Epidemiological, clinical characteristics and outcome of severe scorpion envenomation in South Tunisia: multivariate analysis of 951 cases. Toxicon; 2008 Dec 15;52(8):918-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of scorpion envenomation was based on a history of scorpion sting.
  • There were 769 patients (80.8%) in the grade III group (with cardiogenic shock and/or pulmonary edema or severe neurological manifestation (coma and/or convulsion)) and 182 patients (19.2%) in the grade II group (with systemic manifestations).
  • [MeSH-major] Scorpion Stings / diagnosis. Scorpion Stings / epidemiology. Scorpion Venoms / poisoning. Scorpions

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930073.001).
  • [ISSN] 0041-0101
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Scorpion Venoms
  •  go-up   go-down


41. Attia EA, Abdallah M, Saad AA, Afifi A, El Tabbakh A, El-Shennawy D, Ali HB: Circulating CD4+ CD25 high FoxP3+ T cells vary in different clinical forms of leprosy. Int J Dermatol; 2010 Oct;49(10):1152-8
MedlinePlus Health Information. consumer health - Mycobacterial Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into; group I tuberculoid (TT), group II borderline cases [borderline tuberculoid (BT), borderline (BB), and borderline lepromatous (BL)], group III lepromatous (LL), and group IV erythema nodosum leprosum (ENL).
  • Comparing the four disease groups, T-regs% was significantly different (median 5.3% in group I, 3.4% in group II, 2.8% in group III, and 1.2% in group IV; P = 0.005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The International Society of Dermatology.
  • (PMID = 20883403.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


42. Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM: Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transpl; 2010 Sep;21(5):898-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the effects of fasting on renal function in CKD patients, we prospectively studied 31 (19 males and mean age 54 ± 14.2 years) CKD patients during the month of Ramadan 1426 Hijra (4th October - 4th November 2005); 14 patients were in stage III CKD, 12 had stage IV and 5 had stage V.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814128.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Hemoglobin A, Glycosylated; 0 / Lipids; 0 / hemoglobin A1c protein, human
  •  go-up   go-down


43. Ghazal-Aswad S: Cervical cancer prevention in the human papilloma virus vaccine era. Ann N Y Acad Sci; 2008 Sep;1138:253-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer prevention in the human papilloma virus vaccine era.
  • Globally, cervical cancer is second only to breast cancer as the leading cause of cancer in women, with a global prevalence of 2.3 million.
  • It is the third most common cause of female cancer-related mortality worldwide, and 82% of new cervical cancer cases occur in developing countries.
  • As stated by WHO, "without screening programs, cervical cancer is detected too late and leads to death in almost all cases."
  • Infection with oncogenic types of HPV 16 and 18 is the most significant risk/causative factor in cervical cancer etiology, and worldwide HPV positivity in cervical carcinoma has been documented to be 99.7%.
  • It targets four HPV types (6, 11, 16, and 18) that are involved in cervical cancer, high and low grade squamous intraepithelial lesions, and anogenital warts.
  • Results from combined Phase II/III studies show that the efficacy of vaccine was 95-100% against LGSIL and HGSIL related to HPV 16 and 18 and vaccine use led to a 99% reduction in the incidence of genital warts (related to HPV 6 and 11).


44. Attia MS, Othman AM, Aboaly MM, Abdel-Mottaleb MS: Novel spectrofluorimetric method for measuring the activity of the enzyme alpha-L-fucosidase using the nano composite optical sensor samarium(III)-doxycycline complex doped in sol-gel matrix. Anal Chem; 2010 Jul 15;82(14):6230-6
Hazardous Substances Data Bank. Samarium, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel spectrofluorimetric method for measuring the activity of the enzyme alpha-L-fucosidase using the nano composite optical sensor samarium(III)-doxycycline complex doped in sol-gel matrix.
  • The method was based upon measuring the quenching of the luminescence intensity of the produced yellow colored complex ion associate of 2-chloro-4-nitrophenol [2-CNP] and a nano composite optical sensor samarium(III)-doxycycline [Sm(3+)-DC](+) complex in a sol-gel matrix at 645 nm.
  • The calibration plot was achieved over the concentration range 3.4 x 10(-9)-1.0 x 10(-6) mol L(-1) [2-CNP] with a correlation coefficient of 0.99 and a detection limit of 6.0 x 10(-10) mol L(-1).

  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560531.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Gels; 0 / Nitrophenols; 42OD65L39F / Samarium; EC 3.2.1.51 / alpha-L-Fucosidase; N12000U13O / Doxycycline; Y2V03M9UL8 / 2-chloro-4-nitrophenol
  •  go-up   go-down


45. Shebl M, Seleem HS, El-Shetary BA: Ligational behavior of thiosemicarbazone, semicarbazone and thiocarbohydrazone ligands towards VO(IV), Ce(III), Th(IV) and UO2(VI) ions: synthesis, structural characterization and biological studies. Spectrochim Acta A Mol Biomol Spectrosc; 2010 Jan;75(1):428-36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ligational behavior of thiosemicarbazone, semicarbazone and thiocarbohydrazone ligands towards VO(IV), Ce(III), Th(IV) and UO2(VI) ions: synthesis, structural characterization and biological studies.
  • Mono- and binuclear VO(IV), Ce(III), Th(IV) and UO(2)(VI) complexes of thiosemicarbazone, semicarbazone and thiocarbohydrazone ligands derived from 4,6-diacetylresorcinol were synthesized.
  • The thiosemicarbazone (H(4)L(1)) and the semicarbazone (H(4)L(2)) ligands behave as dibasic pentadentate ligands in case of VO(IV) and UO(2)(VI) complexes, tribasic pentadentate in case of Ce(III) complexes and monobasic pentadentate in case of Th(IV) complexes.

  • Hazardous Substances Data Bank. URANIUM COMPOUNDS .
  • Hazardous Substances Data Bank. VANADIUM COMPOUNDS .
  • Hazardous Substances Data Bank. THORIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19963432.001).
  • [ISSN] 1873-3557
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Ions; 0 / Ligands; 0 / Semicarbazones; 0 / Thiosemicarbazones; 0 / Uranium Compounds; 0 / Vanadium Compounds; 30K4522N6T / Cerium; 60YU5MIG9W / Thorium; L70487KUZO / uranium dioxide
  •  go-up   go-down


46. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G: Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess; 2010 Nov;14(53):iii-iv, ix-x, 1-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer.
  • BACKGROUND: Anal cancer is uncommon and predominantly a disease of the elderly.
  • Individuals who are human immunodeficiency virus (HIV)-positive are particularly vulnerable to HPV infections, and increasing numbers from this population present with anal cancer.
  • OBJECTIVE: To estimate the cost-effectiveness of screening for anal cancer in the high-risk HIV-positive population [in particular, men who have sex with men (MSM), who have been identified as being at greater risk of the disease] by developing a model that incorporates the national screening guidelines criteria.
  • The following electronic bibliographic databases were searched: Applied Social Sciences Index and Abstracts (ASSIA), BIOSIS previews (Biological Abstracts), British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, NHS Database of Abstracts of Reviews of Effects (DARE), NHS Health Technology Assessment (HTA) Database, PsycINFO, Science Citation Index (SCI), and Social Sciences Citation Index (SSCI).
  • Papers that met the inclusion criteria contained the following: data on population incidence, effectiveness of screening, health outcomes or screening and/or treatment costs; defined suitable screening technologies; prospectively evaluated tests to detect anal cancer.
  • RESULTS: The reference case cost-effectiveness model for MSM found that screening for anal cancer is very unlikely to be cost-effective.
  • The negative aspects of screening included utility decrements associated with false-positive results and with treatment for high-grade anal intraepithelial neoplasia (HG-AIN).
  • However, combined with higher regression rates from low-grade anal intraepithelial neoplasia (LG-AIN), the lowest expected incremental cost-effectiveness ratio remained at over 44,000 pounds per quality-adjusted life-year (QALY) gained.
  • LIMITATIONS: Limited knowledge is available about the epidemiology and natural history of anal cancer, along with a paucity of good-quality evidence concerning the effectiveness of screening.
  • Further studies could assess whether the screening model has underestimated the impact of anal cancer, the results of which may justify an evaluative study of the effects of treatment for HG-AIN.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / economics. HIV Infections / complications. Homosexuality, Male / statistics & numerical data. Mass Screening / economics


47. Shehab A, Elnour AA, Struthers AD: A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc J Afr; 2008 Nov-Dec;19(6):292-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We enrolled eight patients (aged 47 to 72 years, mean = 63.7 years), with New York Heart Association (NYHA) class II-III heart failure and ejection fraction (EF) < 35%, in the study at a university-affiliated hospital in Dundee, Scotland.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. Losartan .
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 6;355(9215):1582-7 [10821361.001]
  • [Cites] J Card Fail. 1999 Sep;5(3):276-82 [10496201.001]
  • [Cites] Eur J Heart Fail. 2000 Dec;2(4):439-46 [11113722.001]
  • [Cites] J Am Coll Cardiol. 2001 Jun 1;37(7):1800-7 [11401114.001]
  • [Cites] Hypertension. 1983 Mar-Apr;5(2 Pt 2):I41-6 [6826228.001]
  • [Cites] Circulation. 1990 Nov;82(5):1724-9 [2146040.001]
  • [Cites] Circulation. 1991 Jun;83(6):1849-65 [1828192.001]
  • [Cites] N Engl J Med. 1991 Aug 1;325(5):293-302 [2057034.001]
  • [Cites] Arch Intern Med. 1992 Apr;152(4):704-10 [1558426.001]
  • [Cites] J Mol Cell Cardiol. 1993 May;25(5):563-75 [8377216.001]
  • [Cites] Hypertension. 1994 Feb;23(2):258-68 [8307637.001]
  • [Cites] Am J Cardiol. 1995 Dec 15;76(17):1259-65 [7503007.001]
  • [Cites] Circulation. 1996 Mar 1;93(5):1043-65 [8598068.001]
  • [Cites] J Card Fail. 1996 Mar;2(1):47-54 [8798105.001]
  • [Cites] Lancet. 1997 Mar 15;349(9054):747-52 [9074572.001]
  • [Cites] Cardiovasc Res. 1997 Jul;35(1):30-4 [9302344.001]
  • [Cites] Circulation. 1997 Oct 7;96(7):2385-96 [9337215.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):709-17 [10471456.001]
  • [Cites] Circulation. 1999 Sep 7;100(10):1056-64 [10477530.001]
  • [Cites] Aging (Milano). 2000 Aug;12(4):315-9 [11073352.001]
  • (PMID = 19104723.001).
  • [ISSN] 1995-1892
  • [Journal-full-title] Cardiovascular journal of Africa
  • [ISO-abbreviation] Cardiovasc J Afr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Mineralocorticoid Receptor Antagonists; 27O7W4T232 / Spironolactone; JMS50MPO89 / Losartan
  • [Other-IDs] NLM/ PMC3971616
  •  go-up   go-down


48. Ain MC, Chang TL, Schkrohowsky JG: Laminectomies and achondroplasia: does body mass index influence surgical outcomes? Am J Med Genet A; 2007 May 15;143A(10):1032-7
Genetic Alliance. consumer health - Achondroplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 49 individuals (mean BMI: 31.5 kg/m(2) at the time of laminectomy) were stratified into the standard BMI categories: normal (<25 kg/m(2)), overweight (25-29.9 kg/m(2)), obese Class I (30-34.9 kg/m(2)), and a combined obese Class II (35-39.9 kg/m(2)) and obese Class III (>40 kg/m(2)).
  • When the study group was categorized into non-obese (normal weight and overweight) and obese (obese Classes I and II/III) groups, there was also no statistically significant improvement difference in terms the same four criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431909.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kreuter A, Brockmeyer NH, Hochdorfer B, Weissenborn SJ, Stücker M, Swoboda J, Altmeyer P, Pfister H, Wieland U: Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol; 2005 Apr;52(4):603-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN) represents a precursor lesion of invasive squamous cell carcinoma with a clear association to high-risk human papillomavirus (HPV) types.
  • HIV infection is strongly associated with a higher prevalence of genital HPV infection, a higher incidence of AIN, and, consecutively, an increased risk for anal cancer.
  • OBJECTIVE: The aim of this study was to determine the clinical spectrum of AIN and lesional HPV colonization in a cohort of homosexual men who were HIV positive and had a history of receptive anal intercourse.
  • RESULTS: Of all patients, 86% had anal HPV infection at their first visit.
  • AIN was diagnosed in 20 of the 103 patients (19.4%).
  • High-risk HPV types were present in all AIN cases with up to 7 different high-risk and up to 5 different low-risk types per lesion.
  • Histologically, 7 (35%), 7 (35%), and 6 (30%) of the patients had AIN grade I, II, or III, respectively.
  • Four different types of clinical presentation could be distinguished in the 20 patients with AIN: bowenoid (1 case, 5%); erythroplakic (2 cases, 10%); verrucous (6 cases, 30%); and leukoplakic (11 cases, 55%).
  • All verrucous lesions were graded as high-grade intraepithelial lesions in cytology, whereas 6 of the 11 leukoplakic lesions (55%) were low grade.
  • All verrucous AIN carried at least 4 different HPV types, always including HPV-16, and the mean number of HPV types was higher in verrucous lesions than in leukoplakic lesions (5.5 vs 3.8, respectively).
  • CONCLUSION: These data confirm the high incidence and prevalence of AIN in patients who are HPV positive with HIV infection.
  • Four different clinical types of AIN can be distinguished that might have prognostic implications.
  • Standardized screening programs for anal cancer prevention and treatment protocols for AIN in patients infected with HIV must be implemented.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793509.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Ding L, Spencer A, Morita K, Han M: The developmental timing regulator AIN-1 interacts with miRISCs and may target the argonaute protein ALG-1 to cytoplasmic P bodies in C. elegans. Mol Cell; 2005 Aug 19;19(4):437-47
SciCrunch. WormBase: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The developmental timing regulator AIN-1 interacts with miRISCs and may target the argonaute protein ALG-1 to cytoplasmic P bodies in C. elegans.
  • We have identified the C. elegans ain-1 gene through a genetic suppressor screen and shown that it functions with the heterochronic genetic pathway that regulates developmental timing.
  • Biochemical analysis indicates that AIN-1 interacts with protein complexes containing an Argonaute protein, Dicer, and miRNAs.
  • AIN-1 shares homology with the candidate human neurological disease protein GW182, shown to localize in cytoplasmic processing bodies that are sites of mRNA degradation and storage.
  • A functional AIN-1::GFP also localizes at the likely worm processing bodies.
  • When coexpressed from transgenes, AIN-1 targets ALG-1 to the foci.
  • These results suggest a model where AIN-1 regulates a subset of miRISCs by localization to the processing bodies, facilitating degradation or translational inhibition of mRNA targets.
  • [MeSH-minor] Animals. Cell Differentiation. Endoribonucleases / genetics. Endoribonucleases / metabolism. Gene Silencing. Molecular Sequence Data. Ribonuclease III

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109369.001).
  • [ISSN] 1097-2765
  • [Journal-full-title] Molecular cell
  • [ISO-abbreviation] Mol. Cell
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AAK32947
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM047869
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIN-1 protein, C elegans; 0 / ALG-1 protein, C elegans; 0 / Caenorhabditis elegans Proteins; 0 / Carrier Proteins; 0 / MicroRNAs; 0 / RNA-Binding Proteins; EC 3.1.- / Endoribonucleases; EC 3.1.26.- / dcr-1 protein, C elegans; EC 3.1.26.3 / Ribonuclease III
  •  go-up   go-down


51. Cashman JP, Guerin SM, Hemsing M, McCormack D: Effect of deferred treatment of supracondylar humeral fractures. Surgeon; 2010 Apr;8(2):71-3
MedlinePlus Health Information. consumer health - Arm Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gartland III and flexion type fractures had a significantly shorter time to surgery than Gartland II (p<0.05).
  • Most common complications identified were ulnar nerve palsy and AIN palsy.
  • Supracondylar fractures which are not grossly displaced, have no neurovascular deficit or risk of skin compromise, can be safely deferred without an increased risk of complication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20303886.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


52. Shim JY, Kim YJ, Lee HS: Effects of soybean isoflavone extract on the plasma lipid profiles and antioxidant enzyme activity in streptozotocin-induced diabetic rats. Nutr Res Pract; 2008;2(4):218-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The one normal control group was fed an AIN-76-based experimental diet and four diabetic groups were fed the same diet, supplemented with four different levels of soybean isoflavone extract for seven weeks.
  • The daily dosages of pure isoflavone for four diabetic groups were set to be 0 mg (diabetic control), 0.5 mg (ISO-I), 3.0 mg (ISO-II) and 30.0 mg (ISO-III) per kilogram of body weight, respectively.
  • The plasma total cholesterol levels and the TBA-reactive substances contents in the liver and kidney were significantly lowered in ISO-II and ISO-III groups compared to those in the diabetic control group.
  • The present study demonstrated the possibility that the diets supplemented with 3.0 mg and 30.0 mg of soybean isoflavone extract may have beneficial effects on the plasma lipids, tissue lipid peroxidation and partly on antioxidant system in diabetic animals and there were no significant differences between the ISO-II and ISO-III groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1995 May;98(5):469-75 [7733126.001]
  • [Cites] Carcinogenesis. 1996 Jan;17(1):73-7 [8565140.001]
  • [Cites] J Ethnopharmacol. 1994 Jul 22;43(3):167-71 [7990489.001]
  • [Cites] Diabetologia. 1993 Nov;36(11):1212-3 [8270140.001]
  • [Cites] Nutr Cancer. 1993;20(1):1-12 [8415125.001]
  • [Cites] Lipids. 1993 Aug;28(8):757-61 [8377591.001]
  • [Cites] Lipids. 1993 Jul;28(7):663-6 [8355596.001]
  • [Cites] J Lipid Res. 1989 Dec;30(12):1827-34 [2621411.001]
  • [Cites] Diabetes Metab Rev. 1987 Apr;3(2):551-70 [3552532.001]
  • [Cites] J Agric Food Chem. 1983 Mar-Apr;31(2):394-6 [6682871.001]
  • [Cites] Clin Chem. 1978 Jun;24(6):931-3 [207463.001]
  • [Cites] Am J Clin Nutr. 1979 Oct;32(10):2143-9 [484533.001]
  • [Cites] Anal Biochem. 1978 May;86(1):271-8 [655387.001]
  • [Cites] Clin Chem. 1973 May;19(5):476-82 [4703655.001]
  • [Cites] Clin Chem. 1974 Apr;20(4):470-5 [4818200.001]
  • [Cites] Clin Chem. 1973 Sep;19(9):1077-8 [4744812.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Nutr Cancer. 2004;49(2):125-30 [15489204.001]
  • [Cites] Life Sci. 2004 Oct 15;75(22):2717-31 [15369706.001]
  • [Cites] Yonsei Med J. 2004 Aug 31;45(4):703-10 [15344213.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3315-20 [12865308.001]
  • [Cites] Diabetes Care. 2002 Oct;25(10):1709-14 [12351466.001]
  • [Cites] Am J Clin Nutr. 2002 Aug;76(2):365-72 [12145008.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Sep;281(3):C1023-8 [11502580.001]
  • [Cites] Diabetes Res Clin Pract. 2001 Jul;53(1):33-9 [11378211.001]
  • [Cites] Free Radic Res. 2001 Jan;34(1):101-12 [11234992.001]
  • [Cites] Obstet Gynecol. 2001 Jan;97(1):109-15 [11152918.001]
  • [Cites] Am J Clin Nutr. 2000 Sep;72(3):844-52 [10966908.001]
  • [Cites] Life Sci. 2006 Sep 13;79(16):1578-84 [16831449.001]
  • [Cites] Singapore Med J. 2006 Aug;47(8):670-5 [16865205.001]
  • [Cites] Diabetes Metab Res Rev. 2006 May-Jun;22(3):190-7 [16216038.001]
  • [Cites] Diabetes. 2006 Apr;55(4):1043-50 [16567527.001]
  • [Cites] J Nutr Biochem. 2005 Nov;16(11):693-9 [16081264.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] J Nutr. 1998 Jun;128(6):954-9 [9614153.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S [10479219.001]
  • [Cites] J Nutr. 1999 Mar;129(3):758S-767S [10082786.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4252-63 [9751507.001]
  • [Cites] Biochem J. 1996 Dec 15;320 ( Pt 3):855-63 [9003372.001]
  • [Cites] Br J Nutr. 1996 Dec;76(6):891-7 [9014657.001]
  • [Cites] J Nutr. 1996 Jan;126(1):43-50 [8558324.001]
  • [Cites] J Nutr. 1996 Jan;126(1):161-7 [8558297.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):624S-630S [7884544.001]
  • (PMID = 20016722.001).
  • [ISSN] 2005-6168
  • [Journal-full-title] Nutrition research and practice
  • [ISO-abbreviation] Nutr Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2788194
  • [Keywords] NOTNLM ; Soybean isoflavone extract / antioxidant / diabetic rat / lipid profiles
  •  go-up   go-down


53. Salem SA, Farouk HM, Mostafa AA, Hassan IM, Osman WM, Al-Shamy HA, Assaf NY: Keratinocyte and lymphocyte apoptosis: relation to disease outcome in systemic lupus erythematosus patients with and without cutaneous manifestations. Eur J Dermatol; 2010 Jan-Feb;20(1):35-41
MedlinePlus Health Information. consumer health - Lupus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 50 systemic lupus erythematosus patients [25 with cutaneous manifestations (group I), 25 without cutaneous manifestations (group II)] and 20 normal controls (group III) were studied.
  • Assessments of disease activity, peripheral lymphocyte apoptosis, macrophage function and apoptotic cells in skin and renal biopsies were carried out.
  • The mean percentage of peripheral apoptotic lymphocytes was significantly higher in group I than groups II, III (55.3 +/- 21.4, 25.6 +/- 8.7 & 19.4 +/- 3.2 respectively, P < 0.001), so was serum neopterin level (27.5 +/- 7.3, 14.9 +/- 2.7, 9.4 +/- 1.1 respectively, p < 0.001), and the mean number of protein53 positive apoptotic keratinocytes in skin (20.6 +/- 5.4, 1.6 +/- 0.5, 1.7 +/- 0.4 respectively, p < 0.001).
  • The mean number of protein53 positive apoptotic skin keratinocytes showed a significant positive correlation to disease activity, percentage of peripheral apoptotic lymphocytes and serum neopterin (P < 0.001).
  • [MeSH-minor] Adult. Complement C4 / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neopterin / blood. Skin / pathology. Tumor Suppressor Protein p53 / analysis. Young Adult


54. Wong AK, Chan RC, Aggarwal N, Singh MK, Nichols WS, Bose S: Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies. Mod Pathol; 2010 Jan;23(1):144-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies.
  • Human papillomavirus (HPV) infection strongly correlates with the development of anal intraepithelial neoplasias and carcinomas; however, few studies have characterized the distribution of the specific subtypes of the virus in the varying grades of dysplasia.
  • This report characterizes the distribution of HPV 16/18 in surgical specimens with anal intraepithelial neoplasia (AIN) I-III and histological variants of anal carcinoma.
  • A total of 111 anal surgical specimens with no dysplasia (10), AIN I-III (53), and anal carcinomas (48) were evaluated for the presence of high-risk HPV infection and subtyped by nested PCR or the Invader Assay.
  • High-risk virus types were detected in progressively greater number of anal intraepithelial lesions from 56% in low grade to 88% in high grade.
  • Type 16 was the prevalent subtype and was noted in 28% of low grade and 68% of high-grade lesions.
  • Moderate dysplasias showed type 16 in 20%, a prevalence similar to that in low-grade lesions.
  • The non-16/18 subtypes of the virus predominated and were present in 50% of the cases.
  • Most (89%) squamous carcinomas were associated with high-risk viruses, 68% with type 16, a prevalence similar to that noted in high-grade dysplasia.
  • Non-16/18 subtypes were encountered more frequently in squamous carcinomas from immunodeficient individuals (57% cases) as compared with immunocompetent individuals (18% cases).
  • The similarity in the prevalence of type 16 in high-grade dysplasia and squamous carcinomas suggests that anal intraepithelial lesion III is the true precursor of squamous carcinoma and warrants aggressive management.
  • Anal intraepithelial lesions II showed a virus distribution that was similar to low-grade dysplasia.
  • In addition, a subset of these that were associated with type 16 or 18 showed progression, whereas those associated with non-16/18 subtypes regressed, thereby raising the possibility of conservative management for these lesions.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. Papillomavirus Infections / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / analysis. Female. Genotype. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Prevalence. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838162.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


55. Shebl M: Synthesis and spectroscopic studies of binuclear metal complexes of a tetradentate N2O2 Schiff base ligand derived from 4,6-diacetylresorcinol and benzylamine. Spectrochim Acta A Mol Biomol Spectrosc; 2008 Sep;70(4):850-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reaction of the Schiff base ligand with nickel(II), cobalt(II), iron(III), cerium(III), vanadyl(IV) and uranyl(VI) ions in 1:2 molar ratio afforded binuclear metal complexes.
  • Also, reaction of the ligand with several copper(II) salts, including Cl-, NO3-, AcO-, ClO4- and SO42- afforded different metal complexes that reflect the non-coordinating or weakly coordinating power of the ClO(4)(-) anion as compared to the strongly coordinating power of SO42- and Cl- anions.

  • Hazardous Substances Data Bank. Benzylamine .
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997352.001).
  • [ISSN] 1386-1425
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4,6-diacetylresorcinol; 0 / Benzylamines; 0 / Ligands; 0 / Metals, Heavy; 0 / Resorcinols; 0 / Schiff Bases; 31C4KY9ESH / Nitric Oxide; A1O31ROR09 / benzylamine
  •  go-up   go-down


56. Agarwal MM, Dhatt GS, Punnose J: Gestational diabetes: utility of fasting plasma glucose as a screening test depends on the diagnostic criteria. Diabet Med; 2006 Dec;23(12):1319-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (iii) independently could 'rule-out' GDM in an additional 2864 (62.2%), 928 (20.2%), 1510 (32.8%) and 1171 (25.4%) women, at FPG thresholds (with 85% sensitivity);.
  • Regardless of the criteria used, initial testing by FPG can significantly decrease the number of cumbersome OGTTs needed for the diagnosis of GDM.
  • [MeSH-major] Blood Glucose / metabolism. Diabetes, Gestational / diagnosis. Fasting / blood. Prenatal Diagnosis / methods

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116182.001).
  • [ISSN] 0742-3071
  • [Journal-full-title] Diabetic medicine : a journal of the British Diabetic Association
  • [ISO-abbreviation] Diabet. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


57. Abdel-Naser MB, Lotfy RA, Al-Sherbiny MM, Sayed Ali NM: Patients with papular urticaria have IgG antibodies to bedbug (Cimex lectularius) antigens. Parasitol Res; 2006 May;98(6):550-6
MedlinePlus Health Information. consumer health - Hives.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IgG and IgE against salivary gland proteins of bedbug (Cimex lectularius) were assessed in comparison with mosquito (Culex pipiens) and flea (Pulex irritans) antigens in the sera of papular urticaria patients (group I), siblings without papular urticaria (group IIa), patients' parents (group IIb), and healthy controls (group III) (Immunoblotting). Anti-C. lectularius IgG was significantly recognized at 66 and 10 kDa in 40% of group I, besides others ranging from 45 to 107 kDa.
  • Sixty percent of group IIb and 100% of group III significantly identified a band of 12.5 kDa.
  • IgG against C. pipiens was significantly recognized at a range of 18-105 kDa in group I, IIb (115, 7 kDa), and III (58, 50 kDa). Anti-P. irritans IgG was significantly recognized by group I (100, 70 kDa) and group IIa (60, 35 kDa).
  • IgE response was confined to C. pipiens at 115 and 54 kDa in groups I and III, respectively, besides 68 and 58 kDa in group IIa.

  • Genetic Alliance. consumer health - Papular urticaria.
  • MedlinePlus Health Information. consumer health - Bed Bugs.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Insect Biochem Mol Biol. 2003 Jan;33(1):63-71 [12459201.001]
  • [Cites] J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):498-505 [9564803.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1989;90(3):271-3 [2592115.001]
  • [Cites] J Allergy Clin Immunol. 1992 Sep;90(3 Pt 1):386-93 [1527321.001]
  • [Cites] Methods Enzymol. 1983;92:377-91 [6855619.001]
  • [Cites] Clin Rev Allergy. 1983 Jun;1(2):289-302 [6370405.001]
  • [Cites] Dermatology. 2001;202(3):193-7 [11385222.001]
  • [Cites] J Allergy Clin Immunol. 1987 Jun;79(6):947-54 [3584749.001]
  • [Cites] Ann Allergy. 1959 May-Jun;17(3):380-4 [13661752.001]
  • [Cites] Ann Allergy Asthma Immunol. 1996 Sep;77(3):238-44 [8814051.001]
  • [Cites] J Med Entomol. 1990 Jul;27(4):519-22 [2388227.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):819-42, quiz 842-4 [15153881.001]
  • [Cites] J Allergy Clin Immunol. 1994 Mar;93(3):551-5 [8151057.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Ann Allergy Asthma Immunol. 2004 Apr;92(4):446-52 [15104197.001]
  • [Cites] Arch Dermatol. 1989 Feb;125(2):219-22 [2563325.001]
  • [Cites] Ann Allergy. 1989 Aug;63(2):143-6 [2569850.001]
  • [Cites] J Am Mosq Control Assoc. 1991 Jun;7(2):319-21 [1895094.001]
  • [Cites] Int J Dermatol. 1981 Jul-Aug;20(6):411-4 [7021436.001]
  • (PMID = 16425065.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens; 0 / Immunoglobulin G; 0 / Salivary Proteins and Peptides; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


58. Himmel HJ: Possible pathways of CVD processes leading to III-V semiconductors via a two-dimensional growth. Chemphyschem; 2005 Apr;6(4):706-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible pathways of CVD processes leading to III-V semiconductors via a two-dimensional growth.
  • Quantum-chemical calculations were carried out to shed more light upon possible first intermediates formed during chemical vapour deposition (CVD) processes leading to III-V semiconductors.
  • Because some of the systems calculated herein contain a substantial number of atoms (up to 144), it is limited to intermediates on the way to solid AIN.
  • The structures are compared with that of solid AIN in its most stable Wurzit-type structure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881587.001).
  • [ISSN] 1439-4235
  • [Journal-full-title] Chemphyschem : a European journal of chemical physics and physical chemistry
  • [ISO-abbreviation] Chemphyschem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Foad I, Sharawy I, Mostafa E, Margergis M, Hussein T: Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma. J Egypt Natl Canc Inst; 2007 Jun;19(2):163-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
  • BACKGROUND: Postoperative radiotherapy (RT) is the most commonly used adjuvant treatment in high risk endometrial carcinoma (HREC), it reduces the incidence of pelvic relapses but doesn't improve survival.
  • OBJECTIVE: This study was conducted to evaluate the efficacy and safety of concomitant weekly cisplatin and postoperative RT in HREC (stages IB grade 3, IC and IIA) followed by adjuvant cisplatin and weekly paclitaxel.
  • PATIENTS AND METHODS: Eighteen patients with pathologically confirmed endometrial carcinoma were enrolled in this study.
  • Five patients (28%), 4 patients (22%) and 9 patients (50%) presented with stages IB grade 3, IC and IIA respectively.
  • RESULTS: Between May 2000 and March 2002, a total of 18 patients with pathologically confirmed endometrial carcinoma, presented to Radiation Oncology & Nuclear Medicine Department, Ain Shams University Hospitals, were enrolled in this study.
  • Grade 3 hematological toxicities, leucopenia, neutropenia and anemia were recorded in one patient (5.6%) each during adjuvant chemotherapy.
  • Randomized phase III studies with large number of patients are necessary to evaluate the benefits of this approach.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Ovariectomy. Paclitaxel / administration & dosage. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19034346.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Mostafa E, Nasar MN, Rabie NA, Ibrahim SA, Barakat HM, Rabie AN: Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. J Egypt Natl Canc Inst; 2006 Dec;18(4):348-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
  • PURPOSE: To evaluate the efficacy and outcome of neoadjuvant paclitaxel and cisplatin chemotherapy followed by concurrent cisplatin and irradiation in patients with locally advanced nasopharyngeal (NP) squamous cell carcinoma.
  • PATIENTS AND METHODS: The trial included 36 patients with locally advanced nasopharyngeal squamous carcinoma presented to Radiation Oncology and Otolaryngology departments-Ain Shams university hospitals, and Sohag Cancer Center between November 2002 and March 2006.
  • Survival and PFS were significantly better for patients with smaller tumor volume (stage III), compared with patients with stage IV.
  • Neutropenia (25%), mucositis (22%) and vomiting (20%) were the most severe toxicities recorded (grade 3 and 4) during IC while mucositis (36%), dermatitis (28%), anemia (14%) and vomiting (14%) were the most pronouncing toxicities (grade 3 and 4) during CCRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Paclitaxel / administration & dosage. Radiotherapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301458.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


61. El-Shinawi M, Abdelwahab SF, Sobhy M, Nouh MA, Sloane BF, Mohamed MM: Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach. Ann Surg Oncol; 2010 Oct;17(10):2677-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In breast cancer patients, venous drainage of the breast may contain cells of immunological importance, tumor cells undergoing dissemination, and other biological factors derived from the tumor microenvironment.
  • Aims were to (1) develop a surgical approach to collect blood from the breast tumor microenvironment through tributaries of the axillary vein and (2) characterize and compare immune cells collected from the axillary vein with those in peripheral blood of breast cancer patients.
  • MATERIALS AND METHODS: We enrolled 17 women aged 30-50 years and diagnosed with breast cancer by mammography, ultrasound, and biopsy (stages II-III).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2007 Jul;31(7):1382-6 [17514508.001]
  • [Cites] Cancer Cell. 2009 Aug 4;16(2):91-102 [19647220.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2704-15 [18565863.001]
  • [Cites] Egypt J Immunol. 2006;13(2):11-22 [18689267.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3083-91 [18787906.001]
  • [Cites] Indian J Cancer. 2009 Jan-Mar;46(1):54-60 [19282568.001]
  • [Cites] Ann Thorac Surg. 2009 Jun;87(6):1669-75 [19463575.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):957-64 [12461568.001]
  • [Cites] Surgery. 2003 Nov;134(5):827-34 [14639362.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):147-8 [15003196.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4618-23 [15034080.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Breast Cancer Res Treat. 1990 Dec;17(2):77-82 [2096995.001]
  • [Cites] Eur J Cancer. 1992;28A(4-5):859-64 [1524909.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4140-5 [7545086.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1708-15 [9057654.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1B):571-6 [9568179.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] East Mediterr Health J. 2003 May;9(3):448-63 [15751939.001]
  • [Cites] Cancer Immunol Immunother. 2005 Aug;54(8):721-8 [16010587.001]
  • [Cites] PLoS Med. 2005 Sep;2(9):e284 [16124834.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):259-67 [16404427.001]
  • [Cites] Clinics (Sao Paulo). 2006 Jun;61(3):203-8 [16832552.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5373-80 [17135638.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):354-61 [17210718.001]
  • [Cites] J Exp Med. 2007 May 14;204(5):1037-47 [17438063.001]
  • [Cites] Cancer Cell. 2009 Aug 4;16(2):81-2 [19647215.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2413-20 [18413832.001]
  • (PMID = 20333554.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131990
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS385125; NLM/ PMC3402355
  •  go-up   go-down


62. Tantawy AA, El-Bostany EA, Adly AA, Abou El Asrar M, El-Ghouroury EA, Abdulghaffar EE: Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis; 2010 Jan;21(1):28-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic variations of the enzymes involved in chemotherapy metabolism in cancer patients may play a role in determining relapse and toxicity risks.
  • The present study aimed to assess the prevalence of MTHFR polymorphisms C677>T and A1298>C in Egyptian children with ALL and the relation to the frequency of drug-induced complications and relapse rate.
  • Methotrexate therapy was significantly associated with increased grade III/IV toxicity in TT genotype: diarrhea in 81.3%, oral mucositis in 81.3%, elevated transaminases in 87.5%, neutropenia in 78.7% compared to values of 7.7, 7.7, 15.3, and 7.7% in CC genotype, respectively (P < 0.0001, P < 0.0001, P < 0.0001, and P = 0.03).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood Coagul Fibrinolysis. 2010 Mar;21(2):200
  • (PMID = 19923983.001).
  • [ISSN] 1473-5733
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


63. Bassiony AA, Abdelrahman M, Abdelhady A, Assal MK: Resection arthrodesis for the management of aggressive giant cell tumor of the distal femur. Indian J Orthop; 2009 Jan;43(1):67-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Eight patients with mean age of 37.25 years (range 30-45 years) with Campanacci Grade III (Enneking stage III) giant cell tumors at the distal femur were treated with wide resection and arthrodesis using dual free fibular graft and locked intramedullary nail from January 2003 to January 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1996 Mar;78(2):264-9 [8666639.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1998 May;80(5):636-47 [9611024.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):215-8 [10738888.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jul;(388):167-77 [11451116.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):5-12 [14765857.001]
  • [Cites] Ann Acad Med Singapore. 2005 Apr;34(3):235-7 [15902343.001]
  • [Cites] J Surg Oncol. 2005 Oct 1;92(1):46-51 [16180228.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):35-51 [16311110.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):96-9 [16462511.001]
  • [Cites] J Bone Joint Surg Br. 2006 Dec;88(12):1642-6 [17159179.001]
  • [Cites] Indian J Orthop. 2007 Apr;41(2):124-8 [21139764.001]
  • [Cites] Indian J Orthop. 2007 Apr;41(2):129-33 [21139765.001]
  • [Cites] J Bone Joint Surg Am. 1990 Dec;72(10):1477-85 [2254355.001]
  • [Cites] J Bone Joint Surg Am. 1990 Apr;72(4):486-94 [2324134.001]
  • [Cites] J Orthop Res. 1989;7(4):463-7 [2738764.001]
  • [Cites] Clin Orthop Relat Res. 1987 Aug;(221):188-201 [3301143.001]
  • [Cites] Arch Orthop Trauma Surg. 1986;105(2):67-72 [3718192.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1970 May;25(5):1061-70 [4910256.001]
  • [Cites] J Bone Joint Surg Br. 1994 Mar;76(2):178-86 [8113272.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jan;79(1):36-42 [9020442.001]
  • (PMID = 19753183.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2739496
  • [Keywords] NOTNLM ; Giant cell tumor / intra medullary nail / resection arthrodesis
  •  go-up   go-down


64. Bernieh B, Boobes Y, Al Hakim MR, Abouchacra S, Dastoor H: Long-term use of low-molecular-weight heparin in hemodialysis patients: a 7-year experience. Blood Purif; 2009;27(3):242-5
MedlinePlus Health Information. consumer health - Dialysis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: During 7 years of the use of the LMWH enoxaparin (EN), 236 patients were treated with a total number of 60,987 HD sessions.
  • The long-term effects of EN on the platelet count and lipid profile were comparable to unfractionated heparin.
  • CONCLUSION: The long-term use of LMWH (EN) with a reduced dose in HD is practical and safe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19190397.001).
  • [ISSN] 1421-9735
  • [Journal-full-title] Blood purification
  • [ISO-abbreviation] Blood Purif.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Enoxaparin
  •  go-up   go-down


65. Dedes KJ, Beneder C, Samartzis N, Muller MD, Fink D, Fehr MK: Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women. J Reprod Med; 2008 Dec;53(12):947-51
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women.
  • OBJECTIVE: To determine characteristics and clinical course of high-grade anogenital intraepithelial neoplasia (AIN) in human immunodeficiency virus (HIV)-infected women.
  • STUDY DESIGN: HIV-positive women with biopsy-proven high-grade (II and III) vulvar (VIN), vaginal (VAIN) or perianal intraepithelial neoplasia (PAIN) were identified in the electronic databases of 2 colposcopy clinics.
  • Of the patients, 77.4% had VIN, 12.9% VAIN and 9.7% PAIN at first diagnosis.
  • Age at diagnosis of IN was 36.2 years (SD +/- 5.2; range, 23.5-47.0).
  • Ninety percent of patients received antiretroviral therapy at first diagnosis of IN; 65% (13 of 20) of patients with a follow-up of > 2 years required a second treatment, and 2 developed invasive vulvar cancer (10%).
  • CONCLUSION: AIN among HIV-positive women shows a high relapse rate despite treatment modality used and a substantial invasive potential.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma in Situ / therapy. HIV Infections / complications. Vaginal Neoplasms / therapy. Vulvar Neoplasms / therapy


66. Wainwright PE, Lomanowska AM, McCutcheon D, Park EJ, Clandinin MT, Ramanujam KS: Postnatal dietary supplementation with either gangliosides or choline: effects on spatial short-term memory in artificially-reared rats. Nutr Neurosci; 2007 Feb-Apr;10(1-2):67-77
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Male Long-Evans rats were reared artificially from postnatal days (PD) 5-18 and were fed diets containing either (i) choline chloride 1250 mg/l (CHL), (ii) choline chloride 250 mg/l and GD3 24 mg/l (GNG) or (iii) choline chloride 250 mg/l (STD).
  • Rats were weaned onto AIN 93G diet and on PD 35 were trained on a cued delayed- matching-to-place version of the Morris water maze.

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539485.001).
  • [ISSN] 1028-415X
  • [Journal-full-title] Nutritional neuroscience
  • [ISO-abbreviation] Nutr Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gangliosides; N91BDP6H0X / Choline
  •  go-up   go-down


67. Rizk DE, Fahim MA, Hassan HA, Al-Marzouqi AH, Ramadan GA, Al-Kedrah SS, Al-Ghafri LS: The effect of ovariectomy on biomarkers of urogenital ageing in old versus young adult rats. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep;18(9):1077-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One month later, biomarkers of urogenital ageing were evaluated (light microscopic count of urethral and anal canal submucosal blood vessels, Western blot analysis of urethral, and anal canal submucosal collagen I and III and cytoplasmic p27(kip1) expression in the striated urethral and anal sphincters and levator ani and gel electrophoresis of isomyosin I proportion in these muscles) and compared in all groups (n = 24).
  • [MeSH-major] Aging / metabolism. Collagen Type I / metabolism. Collagen Type III / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Ovariectomy. Urethra / blood supply. Urethra / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1996;7(1):30-6 [8798084.001]
  • [Cites] Hormones (Athens). 2005 Jan-Mar;4(1):9-17 [16574627.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2007 Apr;18(4):413-8 [16900438.001]
  • [Cites] Orv Hetil. 2006 Mar 12;147(10):441-8 [16573173.001]
  • [Cites] J Muscle Res Cell Motil. 2002;23(4):335-9 [12630708.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):80-8 [16932262.001]
  • [Cites] Neurourol Urodyn. 1998;17(3):197-205 [9590471.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):401-4 [16007351.001]
  • [Cites] Exp Physiol. 2005 Jan;90(1):87-93 [15466459.001]
  • [Cites] J Am Geriatr Soc. 2006 Mar;54(3):405-12 [16551306.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Apr;278(4):R964-72 [10749785.001]
  • [Cites] BMC Clin Pathol. 2001;1(1):4 [11696252.001]
  • [Cites] Neuromuscul Disord. 2005 Jan;15(1):48-56 [15639121.001]
  • [Cites] Urol Res. 2003 Jul;31(3):147-51 [12669156.001]
  • [Cites] Neurourol Urodyn. 2005;24(1):44-50 [15573382.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jan;192(1):80-8 [15672007.001]
  • [Cites] Urology. 2005 Dec;66(6):1343-8 [16360481.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1741-51 [15902188.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):481-7 [15521940.001]
  • [Cites] J Anat. 2001 Nov;199(Pt 5):599-607 [11760891.001]
  • [Cites] Am J Obstet Gynecol. 2006 Jan;194(1):100-4 [16389017.001]
  • [Cites] J Urol. 2005 Mar;173(3):1022-6 [15711369.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):620-7 [15041990.001]
  • (PMID = 17205219.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Collagen Type III; 0 / Estrogens; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


68. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid; 2006 Dec;16(12):1229-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
  • This analysis was performed to determine the effect of initial therapy on the outcomes of thyroid cancer patients.
  • Patients were stratified as low risk (stages I and II) or high risk (stages III and IV).
  • Near-total thyroidectomy followed by radioactive iodine therapy, and moderate thyroid hormone suppression therapy, both predicted improved overall survival in stage II patients.
  • No treatment modality, including lack of radioactive iodine, was associated with altered survival in stage I patients.
  • We also conclude that radioactive iodine therapy is beneficial for stage II, III, and IV patients.
  • Importantly, we show for the first time that superior outcomes are associated with aggressive thyroid hormone suppression therapy in high-risk patients, but are achieved with modest suppression in stage II patients.
  • We were unable to show any impact, positive or negative, of specific therapies in stage I patients.
  • [MeSH-major] Carcinoma, Papillary / therapy. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2007 Jun;17(6):595-6; author reply 596-7 [17614785.001]
  • (PMID = 17199433.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16524
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antithyroid Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


69. Srikumaran U, Tan EW, Erkula G, Leet AI, Ain MC, Sponseller PD: Pin size influences sagittal alignment in percutaneously pinned pediatric supracondylar humerus fractures. J Pediatr Orthop; 2010 Dec;30(8):792-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our goal was to review our experience with Wilkins-modified Gartland type-III pediatric supracondylar humerus fractures treated with closed reduction and percutaneous pinning to evaluate the effects of pin size within 2 different pin constructs on maintenance of reduction and on the risk of surgical complications.
  • METHODS: We retrospectively reviewed the medical records of pediatric patients with Wilkins-modified Gartland type-III supracondylar humerus fractures that were closed reduced and percutaneously pinned at our institution from March 1999 through December 2008.
  • LEVEL OF EVIDENCE: Level III Therapeutic Study.

  • MedlinePlus Health Information. consumer health - Arm Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21102203.001).
  • [ISSN] 1539-2570
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Suryanarayana P, Saraswat M, Petrash JM, Reddy GB: Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Mol Vis; 2007;13:1291-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Diabetes was induced in Wistar-NIN rats by STZ (35 mg/kg body weight, intraperitoneally) and the animals were divided into three groups (Group II, III, and IV).
  • While Group I and Group II animals received AIN-93 diet, rats in Groups III and IV received 0.2% of standardized mixture of Emblica tannoids and 2% of Emblica pericarp, respectively, in an AIN-93 diet for a period of eight weeks.

  • MedlinePlus Health Information. consumer health - Cataract.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679931.001).
  • [ISSN] 1090-0535
  • [Journal-full-title] Molecular vision
  • [ISO-abbreviation] Mol. Vis.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY02687; United States / NEI NIH HHS / EY / EY05856
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Blood Glucose; 0 / Cross-Linking Reagents; 0 / Crystallins; 0 / Insulin; 0 / Polymers; 0 / Tannins; 0 / polyol; 5W494URQ81 / Streptozocin
  •  go-up   go-down


71. Lu X, Miyachi S, Ito Y, Nambu A, Takada M: Topographic distribution of output neurons in cerebellar nuclei and cortex to somatotopic map of primary motor cortex. Eur J Neurosci; 2007 Apr;25(8):2374-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 3 days after rabies injections into proximal forelimb, distal forelimb and hindlimb representations of the macaque MI, second-order neurons via the thalamus were labeled in the deep cerebellar nuclei, including the dentate (DN), anterior interpositus (AIN) and posterior interpositus nuclei.
  • The same rostrocaudal arrangement was observed in the AIN.
  • However, the hindlimb labeling was seen both rostral and lateral to that of the proximal forelimb within lobules III-VI.
  • These results indicate that the hindlimb, proximal forelimb and distal forelimb are arranged rostrocaudally in the DN and AIN, whereas there is dual somatotopy along the rostrocaudal and lateromedial axes in the cerebellar cortex.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445235.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


72. Khalil SS, Silverman HJ, Raafat M, El-Kamary S, El-Setouhy M: Attitudes, understanding, and concerns regarding medical research amongst Egyptians: a qualitative pilot study. BMC Med Ethics; 2007;8:9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted semi-structured interviews with 15 Egyptian individuals recruited from the outpatient settings (public and private) at Ain Shams University in Cairo, Egypt.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jul 12;345(2):139-42 [11450665.001]
  • [Cites] East Mediterr Health J. 2006;12 Suppl 1:S50-5 [17037689.001]
  • [Cites] IRB. 1998 Jul-Aug;20(4):1-7 [11657084.001]
  • [Cites] J Intern Med. 2002 Feb;251(2):156-68 [11905591.001]
  • [Cites] Bull World Health Organ. 2002;80(2):114-20 [11953789.001]
  • [Cites] Soc Sci Med. 2002 Apr;54(7):1131-41 [11999507.001]
  • [Cites] Soc Sci Med. 2002 Sep;55(5):709-19 [12190265.001]
  • [Cites] N Engl J Med. 2003 Apr 3;348(14):1383-6 [12672867.001]
  • [Cites] J Med Ethics. 2004 Feb;30(1):68-72 [14872079.001]
  • [Cites] Bull Med Ethics. 2002 Oct;(182):17-23 [14983848.001]
  • [Cites] J Med Philos. 2004 Apr;29(2):149-78 [15371185.001]
  • [Cites] Bioethics. 2004 Sep;18(5):448-70 [15462026.001]
  • [Cites] MCN Am J Matern Child Nurs. 1981 May-Jun;6(3):171-6 [6787363.001]
  • [Cites] JAMA. 1982 Aug 27;248(8):968-70 [7097966.001]
  • [Cites] Hastings Cent Rep. 1987 Apr;17(2):20-4 [3294743.001]
  • [Cites] Soc Sci Med. 1991;32(1):35-42 [2008619.001]
  • [Cites] Law Med Health Care. 1991 Fall-Winter;19(3-4):207-13 [1779688.001]
  • [Cites] Soc Sci Med. 1992 Nov;35(9):1079-91 [1439926.001]
  • [Cites] N Engl J Med. 1997 Jan 30;336(5):370-3 [9011793.001]
  • [Cites] Aust N Z J Public Health. 1998 Aug;22(5):528-31 [9744203.001]
  • [Cites] BMJ. 1998 Oct 31;317(7167):1209-12 [9794861.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1554-9 [9893627.001]
  • [Cites] Soc Sci Med. 1999 Jan;48(2):139-48 [10048773.001]
  • [Cites] BMJ. 1999 Apr 24;318(7191):1114-7 [10213724.001]
  • [Cites] Health Technol Assess. 2005 Mar;9(8):1-192, iii-iv [15763039.001]
  • [Cites] J Nutr. 2005 Apr;135(4):925-8 [15795463.001]
  • [Cites] IRB. 2005 Mar-Apr;27(2):1-5 [15948324.001]
  • [Cites] IRB. 2005 Nov-Dec;27(6):1-8 [16425478.001]
  • [Cites] IRB. 1989 Sep-Oct;11(5):8-10 [11650254.001]
  • (PMID = 17727728.001).
  • [ISSN] 1472-6939
  • [Journal-full-title] BMC medical ethics
  • [ISO-abbreviation] BMC Med Ethics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2134924
  •  go-up   go-down


73. Bassiony AA: Giant cell tumour of the distal radius: wide resection and reconstruction by non-vascularised proximal fibular autograft. Ann Acad Med Singapore; 2009 Oct;38(10):900-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumour of the distal radius: wide resection and reconstruction by non-vascularised proximal fibular autograft.
  • Out of the various reconstructive procedures described, non-vascularised fibular autograft has been widely used with satisfactory functional results.
  • MATERIALS AND METHODS: Ten patients with a mean age of 33.4 years, with either Campanacci grade II or III histologically proven giant cell tumours of lower end radius were treated with wide excision and reconstruction with ipsilateral non-vascularised proximal fibular autograft.
  • Non-union occurred in 1 case.
  • Reconstruction with non-vascularised fibular graft, internal fixation with DCP with primary corticocancellous bone grafting with transfixation of the fibular head and wrist ligament reconstruction minimises the problem and gives satisfactory functional results.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890583.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


74. Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, Cavagnini F, Facchini G, Abbruzzese A, Hofland LJ, Vitale G: Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets; 2009 Aug;9(5):690-704
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interferon-a (IFN-a) is currently the most used cytokine in the treatment of cancer.
  • In this regard, we have shown that IFN-a, at growth inhibitory concentrations, enhances the EGF-dependent Ras-->Erk signalling and decreases the adenylate cyclase/cAMP pathway activity in cancer cells; both effects represent escape mechanisms to the growth inhibition and apoptosis induced by IFN-a.
  • The selective targeting of these survival pathways might enhance the antitumor activity of IFN-ain cancer cells, as shown by: i) the combination of selective EGF receptor tyrosine kinase inhibitor (gefitinib) and IFN-a having cooperative anti-tumour effects;.
  • iii) the cAMP reconstituting agent (8-Br-cAMP) enhancing the pro-apoptotic activity of IFN-alpha.
  • The emergence of long-acting pegylated forms of IFN-beta makes this agent a promising anti-cancer drug.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508175.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Type I
  • [Number-of-references] 155
  •  go-up   go-down


75. Sayed S, Fischer S, Karck M, Hassouna A, Haverich A: Effect of different preoperative patient characteristics on coronary surgery outcome: a comparative study between a developing and a developed country. J Card Surg; 2009 May-Jun;24(3):275-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty patients were operated at Ain Shams University in Cairo (Egypt) between March and September 1999, compared with 60 patients operated at Hannover medical school (Germany) between March and September 2001.
  • Seventy percent of the Egyptian patients presented in New York Heart Association (NYHA) class III, whereas 50% of the German patients were in NYHA class II.


76. Shehab S, McGonigle D, Hughes DI, Todd AJ, Redgrave P: Anatomical evidence for an anticonvulsant relay in the rat ventromedial medulla. Eur J Neurosci; 2005 Sep;22(6):1431-44
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (ii) confocal microscopy which showed labelled terminals in close association with reticulospinal cell bodies; and (iii) electron microscopy which showed vlPRF terminals making synaptic contact with reticulospinal neurons.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190897.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Fluorescent Dyes; 0 / biotinylated dextran amine; 6SO6U10H04 / Biotin; EC 4.1.1.15 / Glutamate Decarboxylase; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


77. Bean SM, Eltoum I, Horton DK, Whitlow L, Chhieng DC: Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. Am J Surg Pathol; 2007 Apr;31(4):555-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia.
  • Anal intraepithelial neoplasia (AIN) is a human papilloma virus related lesion.
  • The objective of this study is to correlate p16 expression and cellular proliferation measured by Ki-67 staining with the degree of dysplasia in the anal canal and to determine the efficacy of these markers in diagnosing high-grade AIN.
  • Seventy-five anal specimens from 55 patients (37 men; 18 women; mean age: 48 y; median: 44 y; range 25 to 96 y) were studied including 35 normal/reactive lesions, 23 low-grade AIN (AIN I and condyloma), and 17 high-grade AIN (AIN II and III).
  • Expression of p16 in AIN correlated with that of Ki-67 (P<0.001).
  • High-grade AIN often demonstrated p16 staining in more than one-third of the thickness of the epithelium in a diffuse/continuous fashion. p16 expression in low-grade AIN was often restricted to the lower 1/3 of the epithelium and/or was focal and discontinuous.
  • When positive p16 staining was defined as the presence of diffuse/continuous staining in more than one-third of the thickness of epithelium, the sensitivity, specificity, and accuracy of p16 as a marker for diagnosing high-grade AIN were 76%, 86%, and 84%, respectively.
  • When positive Ki-67 staining was defined as the presence of nuclear staining in more than 25% of the cells in more than one-third of the thickness of epithelium, the sensitivity, specificity, and accuracy of Ki-67 as a marker for diagnosing high-grade AIN were 71%, 84%, and 83% respectively.
  • Both p16 and Ki-67 are reliable markers for diagnosing high-grade AIN.
  • [MeSH-major] Anus Neoplasms / diagnosis. Genes, p16. Ki-67 Antigen / metabolism. Papillomavirus Infections / diagnosis. Precancerous Conditions / diagnosis. Tumor Virus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. Female. History, 17th Century. Humans. Immunohistochemistry. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414102.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


78. Badr IH: Potentiometric anion selectivity of polymer-membrane electrodes based on cobalt, chromium, and aluminum salens. Anal Chim Acta; 2006 Jun 16;570(2):176-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metallo-salens of cobalt(II) (Co-Sal), chromium(III) (Cr-Sal), and aluminum(III) (Al-Sal) are used as the active ionophores within plasticized poly(vinyl chloride) membranes.
  • Electron spin resonance (ESR) data indicates that Co(II) metal-ion center of Co-Sal ionophore undergoes oxidation to Co(III).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723397.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Mabrouk GM, Ali EM, El-Rehany MA, El-Samoly HM: TGF-beta1, TNF-alpha and cytochrome c in human astrocytic tumors: a short-term follow up and correlation with survival. Clin Biochem; 2007 Feb;40(3-4):255-60
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta1, TNF-alpha and cytochrome c in human astrocytic tumors: a short-term follow up and correlation with survival.
  • DESIGN AND METHODS: We measured TGF-beta1, TNF-alpha and cytoplasmic cytochrome c in 30 astrocytic tumors Grade II, III and IV.
  • RESULTS: We found that TNF-alpha and cytochrome c release in Grade IV tends to be significantly lower than those in Grade II, whereas TGF-beta1 did not significantly change in the different grades.
  • [MeSH-major] Astrocytoma / diagnosis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Cytochromes c / analysis. Transforming Growth Factor beta1 / analysis. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070791.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; 9007-43-6 / Cytochromes c
  •  go-up   go-down


80. Nada O, Abdel-Hamid M, Ismail A, El Shabrawy L, Sidhom KF, El Badawy NM, Ghazal FA, El Daly M, El Kafrawy S, Esmat G, Loffredo CA: The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma. J Clin Virol; 2005 Oct;34(2):140-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is a major public health problem in Egypt due to the high prevalence of hepatitis C viral (HCV) infection.
  • The HCC cases were graded as: 17.9% Grade I, 32.1% Grade II, 35.7% Grade III and 14.3% were Grade IV.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / virology. Hepacivirus / pathogenicity. Liver Neoplasms / virology. Membrane Glycoproteins / analysis. Membrane Glycoproteins / physiology. Tumor Necrosis Factors / analysis. Tumor Necrosis Factors / physiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157266.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Hepatitis C Antibodies; 0 / Membrane Glycoproteins; 0 / RNA, Viral; 0 / Tumor Necrosis Factors
  •  go-up   go-down


81. Mohamed MH, Gad GI, Ibrahim HY, El Shemi MS, Moustafa MF, Atef SH, Ramadan NM, El Saeid SM: Cord blood resistin and adiponectin in term newborns of diabetic mothers. Arch Med Sci; 2010 Aug 30;6(4):558-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: A total of 60 term newborns were prospectively enrolled and categorized into three groups: 20 were macrosomic infants of pre-gestational diabetic mothers (group I), 20 were non-macrosomic infants of pre-gestational diabetic mothers (group II) and 20 were healthy non-macrosomic infants born to non-diabetic mothers serving as controls (group III).
  • Cord serum resistin correlated positively with cord blood glucose in IDMs in both macrosomic and non-macrosomic groups.
  • Levels were comparable in both macrosomic and non-macrosomic neonates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22371800.001).
  • [ISSN] 1896-9151
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3284071
  • [Keywords] NOTNLM ; adiponectin / infants of diabetic mothers / insulin / macrosomic / resistin
  •  go-up   go-down


82. Attia EA, Seada LS, El-Sayed MH, El-Shiemy SM: Study of telomerase reverse transcriptase (hTERT) expression in normal, aged, and photo-aged skin. Int J Dermatol; 2010 Aug;49(8):886-93
MedlinePlus Health Information. consumer health - Skin Aging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of telomerase reverse transcriptase (hTERT) expression in normal, aged, and photo-aged skin.
  • Telomere-associated cellular senescence contributes to certain age-related cutaneous disorders, including increased cancer incidence.
  • Premature skin aging in xeroderma pigmentosa (XP) is expected to show increased telomere attrition.
  • We aimed to study human telomerase reverse transcriptase (hTERT) expression in normal, aged and photo-aged skin and to investigate its possible role in the pathogenesis of aging and photo-aging.
  • METHODS: hTERT expression using immunohistochemistry was studied in 75 subjects comprising four groups: group I, 10 subjects with aged skin; group II, 20 subjects with photo-aging; group III, Five patients with XP; and group IV, 40 subjects comprising the control groups.
  • RESULTS: We found positive hTERT in normal skin and in the basal and sometimes in supra-basal layers.
  • We reported positive hTERT expression in dermal fibroblasts, histiocytes, and skin appendages (other than hair follicles) in some cases from all the studied groups.
  • Photo-aged and prematurely photo-aged skin showed greater hTERT expression than young and aged skin.
  • [MeSH-major] Aging / metabolism. Epidermis / metabolism. Epidermis / pathology. Skin Aging / physiology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The International Society of Dermatology.
  • (PMID = 21174371.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


83. Abd-Elhamid ES, Elmalahy MH: Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study. Diagn Pathol; 2010;5:72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study.
  • AIMS AND OBJECTIVES: This study aims to analyze immunocytochemically p53 aberrant expression and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma (MEC) of parotid gland and to ascertain if expression of these markers correlates with tumor behavior, clinical outcome, histological grade and local recurrence.
  • Out of 20 cases, 7 were classified as grade I, 8 as grade II and 5 as grade III.
  • The p53 positive cases included 3 cases classified as grade (I), 8 cases as grade (II) and 5 cases as grade (III).
  • The mdm-2 +ve primary cases included 2 classified as grade (I), 7 as grade (II) and 5 as grade (III).
  • CONCLUSIONS: These data suggested that expression of p53 and mdm-2 in primary and recurrent MEC correlates with the high histological grade.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / chemistry. Immunohistochemistry. Neoplasm Recurrence, Local. Parotid Neoplasms / chemistry. Proto-Oncogene Proteins c-mdm2 / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1997;75(9):1302-8 [9155050.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2037-44 [7697591.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):1-4 [9417035.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):195-200 [9419352.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2513-25 [9564034.001]
  • [Cites] J Pathol. 1999 Jan;187(1):112-26 [10341712.001]
  • [Cites] Braz Dent J. 2005;16(2):162-6 [16475613.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):477-83 [10675478.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1840-4 [10815906.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):67-9 [10889922.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):587-96 [10934161.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Mar;54(3):317-25 [11298083.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Dec;30(6):538-44 [11829237.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):433-40 [11839563.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):115-22 [11916503.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1808-15 [12060621.001]
  • [Cites] J Histochem Cytochem. 2002 Nov;50(11):1425-34 [12417607.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6396-405 [12944468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11636-41 [13130078.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4107-14 [7686617.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3226-8 [8324731.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] J Oral Pathol Med. 1997 May;26(5):217-23 [9178173.001]
  • (PMID = 21092204.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC3000838
  •  go-up   go-down


84. Harper CE, Cook LM, Patel BB, Wang J, Eltoum IA, Arabshahi A, Shirai T, Lamartiniere CA: Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate; 2009 Nov 1;69(15):1668-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats.
  • BACKGROUND: Chemoprevention utilizing dietary agents is an effective means to slow the development of prostate cancer.
  • We evaluated the potential additive and synergistic effects of genistein and resveratrol for suppressing prostate cancer in the Simian Virus-40 T-antigen (SV-40 Tag) targeted probasin promoter rat model, a transgenic model of spontaneously developing prostate cancer.
  • METHODS: Rats were fed genistein or resveratrol (250 mg/kg AIN-76A diet) alone and in combination, and a low-dose combination (83 mg genistein + 83 mg resveratrol/kg diet).
  • RESULTS: Genistein, resveratrol, and the high-dose combination treatments suppressed prostate cancer.
  • The low-dose combination did not elicit protection against prostate cancer and was most likely below the effective dose for causing significant histopathological changes.
  • CONCLUSIONS: Genistein and resveratrol, alone and in combination, suppress prostate cancer development in the SV-40 Tag model.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Tissue React. 1996;18(2-3):67-71 [9063768.001]
  • [Cites] J Urol. 1997 Jul;158(1):222-7 [9186364.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):911-5 [9637140.001]
  • [Cites] Prostate. 1998 Sep 15;37(1):36-43 [9721067.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] Endocrinology. 1999 May;140(5):1984-9 [10218945.001]
  • [Cites] J Nutr. 1999 Sep;129(9):1628-35 [10460196.001]
  • [Cites] Natl Cancer Inst Monogr. 1963 Oct;12:1-27 [14072991.001]
  • [Cites] Drug Metab Dispos. 2004 Dec;32(12):1377-82 [15333514.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):148-64 [15389804.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71 [15663989.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1109-16 [15731164.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:201-17 [17261768.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):153-7 [12708490.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2972-82 [12843129.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 30;219(1-2):171-80 [15149738.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):473-86 [15489140.001]
  • [Cites] J Histochem Cytochem. 1989 Jan;37(1):105-13 [2461979.001]
  • [Cites] Lancet. 1993 Nov 13;342(8881):1209-10 [7901532.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5474-8 [7522959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):19900-7 [8702703.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5965-75 [17575167.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1946-53 [17675339.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1576-89 [17705241.001]
  • [Cites] Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):7-14 [18439064.001]
  • [Cites] BMC Cancer. 2009;9:30 [19171036.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2203-8 [10786685.001]
  • [Cites] Methods Mol Biol. 2000;149:III-IV, 1-413 [11028258.001]
  • [Cites] Xenobiotica. 2000 Nov;30(11):1047-54 [11197066.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4693-700 [11406539.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7456-63 [11606380.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Cancer Lett. 2002 Dec 1;186(1):11-8 [12183070.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4945-54 [12208745.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):79-87 [12554065.001]
  • (PMID = 19670229.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / P30 CA-13148-34; United States / NCI NIH HHS / CA / U54 CA100949-010002; United States / NCI NIH HHS / CA / R25 CA047888; United States / NCI NIH HHS / CA / CA100949-010002; United States / NCI NIH HHS / CA / U54-CA10094; United States / NCI NIH HHS / CA / CA 47888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antigens, Polyomavirus Transforming; 0 / Ki-67 Antigen; 0 / Stilbenes; 0 / Trans-Activators; 67763-96-6 / Insulin-Like Growth Factor I; DH2M523P0H / Genistein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / Nuclear Receptor Coactivator 3; Q369O8926L / resveratrol
  • [Other-IDs] NLM/ NIHMS143942; NLM/ PMC2758814
  •  go-up   go-down


85. Rashed RM, El-Alfy SH, Mohamed IK: Histochemical analysis of muscle fiber types of rat superior rectus extraocular muscle. Acta Histochem; 2010 Nov;112(6):536-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five muscle fiber types were recognized within the SRM: I, II, III, IV and V.
  • Low SDH (granular type) and high phosphorylase activity were demonstrated by type III fibers (22.65±1.73μm; 36%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19608220.001).
  • [ISSN] 1618-0372
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.4.1.- / Phosphorylases
  •  go-up   go-down


86. Panemangalore M, Bebe FN: Short- and long-term exposure to low levels of pesticide and flavonoid mixtures modify endogenous antioxidants in tissues of rats. J Environ Sci Health B; 2009 May;44(4):357-64
MedlinePlus Health Information. consumer health - Pesticides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two experiments were conducted using dietary flavonoid (F) and oral pesticide (P) mixtures (FM, PM) on changes in the activities of superoxide dismutase (SOD), glutathione peroxidase (GPX) and glutathione concentrations (GSH) in male Sprague Dawley rats (150-175 g) fed for 2 or 4 weeks the AIN 93M diet with or without equal amounts of quercetin, rutin, catechin (FM) at 1.0 mM or 5 mM/kg diet, and with/without PM fed orally at 0.1 mL/d/5d/wk (PM = chlorpyrifos, endosulfan, thiram at 25% LD(50) in oil).
  • (iii) Liver GPX activity declined in both 2 and 4 week experiments in the FM and PFM groups, respectively.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365751.001).
  • [ISSN] 1532-4109
  • [Journal-full-title] Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes
  • [ISO-abbreviation] J Environ Sci Health B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Flavonoids; 0 / Pesticides; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione
  •  go-up   go-down


87. Al-Salam S, John A, Daoud S, Chong SM, Castella A: Expression of Epstein-Barr virus in Hodgkin lymphoma in a population of United Arab Emirates nationals. Leuk Lymphoma; 2008 Sep;49(9):1769-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HL has three main epidemiological patterns (I, II and III).
  • Type III, which is usually seen in developed countries, is characterised by a low rate in children and a pronounced initial peak in young adults.
  • The third pattern (Type II), which is described in many Asian countries, is intermediate and reflects a transition between types I and III.
  • The proportion of EBV positive HL is low in industrialised countries, high in non-industrialised countries and intermediate in early-industrialised countries.
  • Other sections were examined for the presence of EBV using the immunohistochemical streptavidin-biotin method for the latent membrane protein 1 and in situ hybridisation for EBV encoded RNA to determine the prevalence of EBV in Hodgkin cells and its possible role in the pathogenesis of HL.
  • Nodular sclerosis (NS) subtype was the most common type of HL among UAE nationals followed by mixed cellularity (MC), lymphocytic predominant (LP), unclassified, lymphocytic depletion (LD) and lymphocyte rich (LR) subtypes, respectively.
  • EBV was seen in 17 of 45 (38%) cases of HL and was predominately seen in the MC subtype followed by NS, LD and LR subtypes, respectively.
  • These data indicate that the epidemiology of HL in a native population of the UAE is suggestive of a type II epidemiologic pattern in terms of age distribution, and histopathologic subtypes, whereas the frequency of EBV expression is more suggestive of a type III epidemiologic pattern.


88. Ali MA, Nyberg F, Chandranath SI, Dhanasekaran S, Tariq S, Petroianu G, Hasan MY, Adeghate EA, Adem A: Distribution of neuroendocrine cells in the small and large intestines of the one-humped camel (Camelus dromedarius). Neuropeptides; 2007 Oct;41(5):293-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Camels. Cholecystokinin / analysis. Gastric Inhibitory Polypeptide / analysis. Gastrin-Releasing Peptide / analysis. Immunohistochemistry. Neurokinin A / analysis. Nitric Oxide Synthase Type III / analysis. Sincalide / analysis. Somatostatin / analysis. Substance P / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688943.001).
  • [ISSN] 0143-4179
  • [Journal-full-title] Neuropeptides
  • [ISO-abbreviation] Neuropeptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 333DO1RDJY / Serotonin; 33507-63-0 / Substance P; 51110-01-1 / Somatostatin; 59392-49-3 / Gastric Inhibitory Polypeptide; 80043-53-4 / Gastrin-Releasing Peptide; 86933-74-6 / Neurokinin A; 9011-97-6 / Cholecystokinin; EC 1.14.13.39 / Nitric Oxide Synthase Type III; M03GIQ7Z6P / Sincalide
  •  go-up   go-down


89. Emara AA, Saleh AA, Adly OM: Spectroscopic investigations of new binuclear transition metal complexes of Schiff bases derived from 4,6-diacetylresorcinol and 3-amino-1-propanol or 1,3-diamino-propane. Spectrochim Acta A Mol Biomol Spectrosc; 2007 Nov;68(3):592-604
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reaction of the Schiff base ligands with copper(II), nickel(II), cobalt(II), zinc(II), cadmium(II), iron(III), chromium(III), vanadyl(IV) and uranyl(VI) ions in 1:2 molar ratio afforded the corresponding transition metal complexes.

  • Hazardous Substances Data Bank. PROPANOLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321197.001).
  • [ISSN] 1386-1425
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4,6-diacetylresorcinol; 0 / Diamines; 0 / Ligands; 0 / Propanolamines; 0 / Protons; 0 / Resorcinols; 0 / Schiff Bases; 0 / Transition Elements; 156-87-6 / 3-amino-1-propanol; CB3ISL56KG / trimethylenediamine
  •  go-up   go-down


90. Emara AA, Abou-Hussen AA: Spectroscopic studies of bimetallic complexes derived from tridentate or tetradentate Schiff bases of some di- and tri-valent transition metals. Spectrochim Acta A Mol Biomol Spectrosc; 2006 Jul;64(4):1010-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two ligands react with Co(II), Ni(II), Cu(II), Zn(II), Cd(II), Cr(III) and Fe(III)-nitrates to get binuclear complexes.
  • The H(4)L(a) ligand is a compartmental ligand which hosts the two metal ions at the centers of two cis-N(2)O(2) sites, while the metal complexes of H(2)L(b) ligand are binuclear, where the ligand hosts two metal ions at the centers of two N(2)O sites.
  • In both cases, deprotonation of the hydrogen atoms of the phenolic OH groups occur except in the case of the Ni(II), Fe(III) and Cr(III) complexes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332449.001).
  • [ISSN] 1386-1425
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ligands; 0 / Metals; 0 / Organometallic Compounds; 0 / Schiff Bases; 0 / Transition Elements
  •  go-up   go-down


91. Bakir E: Photophysical properties of clozapine and determination of its concentration by using Eu(III)-dipicolinic acid complex as photo probe. Spectrochim Acta A Mol Biomol Spectrosc; 2010 Jan;75(1):490-2
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photophysical properties of clozapine and determination of its concentration by using Eu(III)-dipicolinic acid complex as photo probe.
  • In addition the activity of clozapine is inhibited of the absorption spectra in the presence of glucose and enhanced in the presence of iron(III).
  • We succeeded in detecting the concentration of clozapine in the range 1-60x10(-9)M using Eu(III)-dipicolinic acid complex as photo probe type and using Stern-Völmer equation to determine the Stern-Völmer constant, critical radius and the mechanism of quenching of luminescence of Eu(III)-dipicolinic acid complex is found to be of dipolar-dipolar interaction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19948424.001).
  • [ISSN] 1873-3557
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Chelating Agents; 0 / Picolinic Acids; 444W947O8O / Europium; J60AR2IKIC / Clozapine; UE81S5CQ0G / dipicolinic acid
  •  go-up   go-down


92. Bernard JE, Butler MO, Sandweiss L, Weidner N: Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol; 2008 May;16(3):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.
  • Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.
  • Immunohistochemistry (IHC) for p16 correlates with human papillomavirus (HPV) integration into the host genome, and HPV subtyping by in situ hybridization (ISH) is now readily available.
  • To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.
  • One hundred thirty-three consecutive anal tissue specimens, from 128 patients were studied.
  • One hundred and eight were anal biopsies and 25 were hemorrhoidectomy specimens.
  • All specimens were stained with hematoxylin and eosin, p16 (Lab Vision), and HPV-ISH (Ventana HPV-III Inform).
  • The comparisons included AIN grade (negative, 1, 2, 3) with nuclear intensity of p16 IHC (0 to 3+), AIN grade with IHC nuclear staining patterns (contiguous, patchy/rare), AIN grade with HPV-ISH [negative, low-risk (LR), high-risk (HR)] and, nuclear intensity of p16 IHC with HPV-ISH.
  • Yet, 33% of AIN negative cases were positive for nuclear p16, although with less nuclear intensity than for AIN2 or 3.
  • The kappa value for AIN/nuclear p16 intensity agreement was 0.61 (ie, substantial agreement).
  • Seventy-nine percent of AIN3 cases were strongly positive for HR, and 9% for LR HPV; whereas 75% of AIN2 were positive for HR and 5% for LR HPV.
  • Forty percent of AIN1 cases were positive for HR and 24% for LR HPV.
  • Yet, 12.5% of AIN negative cases were positive for HPV for both LR and HR types.
  • The kappa value for AIN/HPV agreement was 0.62 (ie, substantial agreement).
  • One hundred percent of HR and 85% of LR HPV were positive for p16.
  • Yet, 6% of negative p16 were positive for HPV (all were LR), whereas 43% of negative HPV showed some p16.
  • Of interest, 30 cases were negative for AIN and p16 staining and of these, 2 (7%) were positive for HPV (both LR subtype).
  • Three cases positive for HR HPV were negative for AIN with only patchy nuclear p16 positivity.
  • We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV
  •  go-up   go-down


93. Mahmoud MS, Abou Gamra MM, Elkhayat MM: Ancylostoma duodenale infection: a study of serum immunoglobulin G4 response to the excretory secretory antigen of adult worm. J Egypt Soc Parasitol; 2005 Apr;35(1):1-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serum anti-Ancylostoma duodenale immunoglobulin (Ig) G4 antibody response to fraction III of the partially purified excretory secretory antigen of adult worm (Ad III ESA) was studied.
  • The serum anti-Ad III ESA IgG & IgG 1-4 subclass antibodies were significantly elevated (P < 0.001) in patients of GI compared with GIII.
  • Detection of serum anti-Ad III ESA IgG4 antibody recorded a 100% sensitivity that was significantly higher (P < 0.001) than IgG1, IgG2 & IgG3, but insignificantly different (P > 0.05) from IgG.
  • [MeSH-minor] Adolescent. Adult. Animals. Child. Cross Reactions. Diagnosis, Differential. Egypt / epidemiology. Enzyme-Linked Immunosorbent Assay. Feces / parasitology. Female. Humans. Male. Middle Aged. Parasite Egg Count. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880990.001).
  • [ISSN] 1110-0583
  • [Journal-full-title] Journal of the Egyptian Society of Parasitology
  • [ISO-abbreviation] J Egypt Soc Parasitol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth; 0 / Immunoglobulin G
  •  go-up   go-down


94. Mostafa E, Khatab A, Al-Adwy ER, Al-Assal GM: Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer. J Egypt Natl Canc Inst; 2007 Mar;19(1):28-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer.
  • PURPOSE: To evaluate the efficacy and outcome of concomitant cisplatin/etoposide and limited field irradiation followed by consolidation docetaxel in patients with locally advanced non small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: This is a prospective phase II study that included 32 patients with locally advanced stage III NSCLC who presented to the Radiation Oncology and Chest Departments- Ain Shams University hospitals, and Sohag Cancer Center between May 2004 and August 2006.
  • Neutropenia (15.5%), anemia (19%), nausea and vomiting (15.5), esophagitis (9%) and pneumonitis (3%) were the most severe, grade 3 and 4, acute toxicities recorded during concomitant chemoradiation and 3 patients (9%) had grade 3 late esophagitis.
  • Neutropenia (35%) and anemia (17%) were the most pronounced, grade 3 and 4, toxicities during consolidation chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839033.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


95. Tit N, Obaidat IM, Alawadhi H: Origins of bandgap bowing in compound-semiconductor common-cation ternary alloys. J Phys Condens Matter; 2009 Feb 18;21(7):075802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The degree of ionicity of all atoms is found to vary linearly with mole fraction x. (ii) There is a strong competition between the anions (Se and Te) in trapping/losing charges and this competition is the main reason for the bandgap bowing character. (iii) There is a reasonable agreement between the calculated results and the available photoluminescence data. (iv) The bowing parameter is found to increase with increasing valence-band offset and increasing lattice mismatch.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21817341.001).
  • [ISSN] 0953-8984
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Emara AA: Structural, spectral and biological studies of binuclear tetradentate metal complexes of N3O Schiff base ligand synthesized from 4,6-diacetylresorcinol and diethylenetriamine. Spectrochim Acta A Mol Biomol Spectrosc; 2010 Sep 15;77(1):117-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The coordination behavior of the H2L towards Cu(II), Ni(II), Co(II), Zn(II), Fe(III), Cr(III), VO(IV) and UO2(VI) ions has been investigated.

  • Hazardous Substances Data Bank. DIETHYLENETRIAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627808.001).
  • [ISSN] 1873-3557
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4,6-diacetylresorcinol; 0 / Anti-Infective Agents; 0 / Ligands; 0 / Metals; 0 / Polyamines; 0 / Resorcinols; 0 / Schiff Bases; 03K6SX4V2J / diethylenetriamine
  •  go-up   go-down


97. Shim JY, Kim KO, Seo BH, Lee HS: Soybean isoflavone extract improves glucose tolerance and raises the survival rate in streptozotocin-induced diabetic rats. Nutr Res Pract; 2007;1(4):266-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One group of normal rats (normal control) was fed an AIN-76-based experimental diet and four groups of diabetic rats were fed the same diet supplemented with four different levels of soybean isoflavone extract for seven weeks.
  • The daily dosages of pure isoflavone for four diabetic groups were set to be 0 mg (diabetic control), 0.5 mg (ISO-I), 3.0 mg (ISO-II) and 30.0 mg (ISO-III) per kilogram of body weight, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Geriatr Med. 1990 Nov;6(4):807-25 [2224748.001]
  • [Cites] Am J Clin Nutr. 2002 Aug;76(2):365-72 [12145008.001]
  • [Cites] Ann Nutr Metab. 1988;32(4):206-14 [3143302.001]
  • [Cites] J Clin Endocrinol Metab. 1995 May;80(5):1685-90 [7745019.001]
  • [Cites] Proc Soc Exp Biol Med. 1995 Jan;208(1):124-30 [7892286.001]
  • [Cites] J Nutr. 1996 Jan;126(1):161-7 [8558297.001]
  • [Cites] Nahrung. 1996 Oct;40(5):281-7 [8921620.001]
  • [Cites] Free Radic Res. 1997 Jan;26(1):63-70 [9018473.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2223-35 [9661587.001]
  • [Cites] Metabolism. 1998 Nov;47(11):1308-14 [9826205.001]
  • [Cites] Am J Clin Nutr. 1998 Dec;68(6 Suppl):1347S-1353S [9848497.001]
  • [Cites] J Nutr. 1999 Mar;129(3):758S-767S [10082786.001]
  • [Cites] Menopause. 1999 Spring;6(1):7-13 [10100174.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S [10479219.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3479-84 [10522983.001]
  • [Cites] Phytother Res. 1999 Nov;13(7):601-8 [10548755.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E491-500 [10710504.001]
  • [Cites] Nutrition. 2000 May;16(5):349-54 [10793303.001]
  • [Cites] Am J Clin Nutr. 2002 Dec;76(6):1191-201 [12450882.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3315-20 [12865308.001]
  • [Cites] Am J Clin Pathol. 1957 Jul;28(1):56-63 [13458125.001]
  • [Cites] Eur J Clin Nutr. 2003 Oct;57(10):1292-4 [14506491.001]
  • [Cites] Nutr Cancer. 2003;47(2):111-7 [15087261.001]
  • [Cites] J Nutr. 2004 Aug;134(8):1874-80 [15284369.001]
  • [Cites] Horm Metab Res. 2004 Aug;36(8):550-8 [15326565.001]
  • [Cites] Nutr Cancer. 2004;49(2):125-30 [15489204.001]
  • [Cites] J Nutr Biochem. 2004 Oct;15(10):583-90 [15542349.001]
  • [Cites] J Nutr Biochem. 2005 Nov;16(11):693-9 [16081264.001]
  • [Cites] Metabolism. 2005 Sep;54(9):1181-8 [16125530.001]
  • [Cites] Life Sci. 2006 Sep 13;79(16):1578-84 [16831449.001]
  • [Cites] Menopause. 2000 Jul-Aug;7(4):236-42 [10914616.001]
  • [Cites] Am J Clin Nutr. 2000 Sep;72(3):844-52 [10966908.001]
  • [Cites] Obstet Gynecol. 2001 Jan;97(1):109-15 [11152918.001]
  • [Cites] Diabetes Care. 2001 Feb;24(2):228-33 [11213870.001]
  • [Cites] J Nutr. 2001 Apr;131(4):1202-6 [11285326.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3053-60 [11443167.001]
  • [Cites] FEBS Lett. 2001 Jul 13;501(1):84-6 [11457461.001]
  • [Cites] J Am Coll Nutr. 2001 Oct;20(5 Suppl):354S-362S; discussion 381S-383S [11603644.001]
  • [Cites] Eur J Nutr. 2001 Aug;40(4):135-46 [11905954.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):156-64 [12094619.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):75-81 [12094632.001]
  • [Cites] Int J Obes. 1986;10(4):293-302 [3095255.001]
  • (PMID = 20368949.001).
  • [ISSN] 2005-6168
  • [Journal-full-title] Nutrition research and practice
  • [ISO-abbreviation] Nutr Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2849033
  • [Keywords] NOTNLM ; Soybean isoflavone extract / diabetic rat / glucose tolerance / streptozotocin / survival rate
  •  go-up   go-down


98. Hamza AA: Ameliorative effects of Moringa oleifera Lam seed extract on liver fibrosis in rats. Food Chem Toxicol; 2010 Jan;48(1):345-55
Hazardous Substances Data Bank. MALONALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the immunohistochemical study showed that Moringa markedly reduced the numbers of smooth muscle alpha-actin-positive cells and the accumulation of collagens I and III in liver.
  • [MeSH-minor] Actins / metabolism. Animals. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Antioxidants / chemistry. Antioxidants / pharmacology. Biphenyl Compounds. Carbon Tetrachloride Poisoning / pathology. Carbon Tetrachloride Poisoning / prevention & control. Collagen / biosynthesis. Ferric Compounds / chemistry. Free Radical Scavengers / pharmacology. Hydroxyproline / metabolism. Immunohistochemistry. Liver / pathology. Liver Function Tests. Male. Malondialdehyde / metabolism. Muscle, Smooth / drug effects. Muscle, Smooth / metabolism. Oxidative Stress / drug effects. Phenols / analysis. Phenols / pharmacology. Picrates. Plant Extracts / therapeutic use. Rats. Seeds / chemistry

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19854235.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antioxidants; 0 / Biphenyl Compounds; 0 / Ferric Compounds; 0 / Free Radical Scavengers; 0 / Phenols; 0 / Picrates; 0 / Plant Extracts; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl; 4Y8F71G49Q / Malondialdehyde; 9007-34-5 / Collagen; RMB44WO89X / Hydroxyproline
  •  go-up   go-down


99. Chedid F, Shanteer S, Haddad H, Musharraf I, Shihab Z, Imran A, Adma HA, Salman N, Rahmani A: Short-term outcome of very low birth weight infants in a developing country: comparison with the Vermont Oxford Network. J Trop Pediatr; 2009 Feb;55(1):15-9
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To determine the outcome of very low birth weight infants (VLBWI) admitted to a level III NICU in UAE and compare the results to percentiles published by the Vermont Oxford Network (VON).
  • Chronic lung disease (CLD) occurred in 12.1% (<P25), death or CLD 26.6%, necrotizing enterocolitis (NEC) 5.8% (<P50), intraventricular hemorrhage (IVH) of any grade 17.5% (P25), grade III or IV IVH in 5% (P25), periventricular leucomalacia (PVL) 2.8% (P50), retinopathy of prematurity stage (ROP) 11.3% (<P10).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650218.001).
  • [ISSN] 1465-3664
  • [Journal-full-title] Journal of tropical pediatrics
  • [ISO-abbreviation] J. Trop. Pediatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Emara AA, El-Sayed BA, Ahmed el-SA: Syntheses, spectroscopic characterization and thermal behavior on novel binuclear transition metal complexes of hydrazones derived from 4,6-diacetylresorcinol and oxalyldihydrazine. Spectrochim Acta A Mol Biomol Spectrosc; 2008 Mar;69(3):757-69
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reactions of the hydrazone ligands with cobalt(II), nickel(II), copper(II), zinc(II), cadmium(II), iron(III) and chromium(III) ions in 1:2 molar ratio afforded the corresponding transition metal complexes.

  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627871.001).
  • [ISSN] 1386-1425
  • [Journal-full-title] Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  • [ISO-abbreviation] Spectrochim Acta A Mol Biomol Spectrosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4,6-diacetylresorcinol; 0 / Hydrazines; 0 / Hydrazones; 0 / Ligands; 0 / Resorcinols; 0 / Schiff Bases; 0 / Transition Elements; 00BH33GNGH / Cadmium; 789U1901C5 / Copper
  •  go-up   go-down






Advertisement